US20230301956A1 - Methods and compositions for treatment of inflammatory disease - Google Patents
Methods and compositions for treatment of inflammatory disease Download PDFInfo
- Publication number
- US20230301956A1 US20230301956A1 US18/069,886 US202218069886A US2023301956A1 US 20230301956 A1 US20230301956 A1 US 20230301956A1 US 202218069886 A US202218069886 A US 202218069886A US 2023301956 A1 US2023301956 A1 US 2023301956A1
- Authority
- US
- United States
- Prior art keywords
- arachidonic acid
- inflammation
- inflammatory
- pufa
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title description 19
- 208000027866 inflammatory disease Diseases 0.000 title description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical group CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 298
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 155
- 230000004054 inflammatory process Effects 0.000 claims abstract description 81
- 150000002148 esters Chemical class 0.000 claims abstract description 40
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 32
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
- 125000004431 deuterium atom Chemical group 0.000 claims abstract description 17
- 235000021342 arachidonic acid Nutrition 0.000 claims description 133
- 206010061218 Inflammation Diseases 0.000 claims description 76
- 229910052805 deuterium Inorganic materials 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 18
- 210000003743 erythrocyte Anatomy 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 abstract description 10
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 description 74
- 241000699670 Mus sp. Species 0.000 description 73
- 229920006008 lipopolysaccharide Polymers 0.000 description 72
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 48
- 239000000047 product Substances 0.000 description 45
- 230000002255 enzymatic effect Effects 0.000 description 43
- 210000004072 lung Anatomy 0.000 description 42
- 238000007254 oxidation reaction Methods 0.000 description 42
- 230000003647 oxidation Effects 0.000 description 41
- 235000005911 diet Nutrition 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 239000003642 reactive oxygen metabolite Substances 0.000 description 32
- 230000000770 proinflammatory effect Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 26
- 230000001225 therapeutic effect Effects 0.000 description 25
- 230000003859 lipid peroxidation Effects 0.000 description 24
- 230000037213 diet Effects 0.000 description 23
- 108010074051 C-Reactive Protein Proteins 0.000 description 22
- 102100032752 C-reactive protein Human genes 0.000 description 22
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 150000002066 eicosanoids Chemical class 0.000 description 19
- 235000020778 linoleic acid Nutrition 0.000 description 19
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 19
- OYHQOLUKZRVURQ-ZVDPVMROSA-N (9z,12z)-11,11-dideuteriooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C([2H])([2H])\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-ZVDPVMROSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 206010030113 Oedema Diseases 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 17
- 230000036542 oxidative stress Effects 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 16
- 238000011068 loading method Methods 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 206010035664 Pneumonia Diseases 0.000 description 14
- 206010003246 arthritis Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000000378 dietary effect Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 11
- 206010069351 acute lung injury Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 230000000737 periodic effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000028709 inflammatory response Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000005502 peroxidation Methods 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100023471 E-selectin Human genes 0.000 description 6
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- -1 lipid peroxides Chemical class 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 102000004420 Creatine Kinase Human genes 0.000 description 5
- 108010042126 Creatine kinase Proteins 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 5
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 5
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003960 inflammatory cascade Effects 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 230000005445 isotope effect Effects 0.000 description 5
- 150000002617 leukotrienes Chemical class 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 230000003331 prothrombotic effect Effects 0.000 description 5
- 238000009790 rate-determining step (RDS) Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 150000003595 thromboxanes Chemical class 0.000 description 5
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 4
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 102100037611 Lysophospholipase Human genes 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 4
- 108010058864 Phospholipases A2 Proteins 0.000 description 4
- 101710164073 Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 208000035868 Vascular inflammations Diseases 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 238000006356 dehydrogenation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000007897 gelcap Substances 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 108091006091 regulatory enzymes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 description 3
- BFWYTORDSFIVKP-VAEKSGALSA-N 15(S)-HPETE Chemical compound CCCCC[C@H](OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-VAEKSGALSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 206010050685 Cytokine storm Diseases 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 3
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 102000003820 Lipoxygenases Human genes 0.000 description 3
- 108090000128 Lipoxygenases Proteins 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 3
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 2
- JSFATNQSLKRBCI-VAEKSGALSA-N 15(S)-HETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RDEYORKJEDLLDB-DQVHGTJVSA-N 5-Hydroperoxyeicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C(\OO)=C\C=C\C(O)=O RDEYORKJEDLLDB-DQVHGTJVSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 2
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010061619 Deformity Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- UFPQIRYSPUYQHK-VRKJBCFNSA-N Leukotriene A4 Natural products CCCCCC=C/CC=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(=O)O UFPQIRYSPUYQHK-VRKJBCFNSA-N 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- 150000002535 isoprostanes Chemical class 0.000 description 2
- SWDSVBNAMCDHTF-UHFFFAOYSA-N isowighteone Chemical compound C1=C(O)C(CC=C(C)C)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 SWDSVBNAMCDHTF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003580 lung surfactant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- SIRZPOBKMRMKDI-UHFFFAOYSA-O 10-(2,5-dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl-triphenylphosphanium Chemical compound OC1=C(OC)C(OC)=C(O)C(C)=C1CCCCCCCCCC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SIRZPOBKMRMKDI-UHFFFAOYSA-O 0.000 description 1
- OIIMUKXVVLRCAF-UHFFFAOYSA-N 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium Chemical compound O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C OIIMUKXVVLRCAF-UHFFFAOYSA-N 0.000 description 1
- GQHZVWMHPQXBIA-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCC(O)CCCCCC=CC=CC=CC=CC(O)=O GQHZVWMHPQXBIA-UHFFFAOYSA-N 0.000 description 1
- XIUKTLIKNFRVRN-UHFFFAOYSA-N 15-oxoicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCC(=O)CCCCCC=CC=CC=CC=CC(O)=O XIUKTLIKNFRVRN-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JYTUBIHWMKQZRB-UHFFFAOYSA-N 4-hydroxyhex-2-enal Chemical compound CCC(O)C=CC=O JYTUBIHWMKQZRB-UHFFFAOYSA-N 0.000 description 1
- JYTUBIHWMKQZRB-ONEGZZNKSA-N 4-hydroxyhexenal Chemical compound CCC(O)\C=C\C=O JYTUBIHWMKQZRB-ONEGZZNKSA-N 0.000 description 1
- UXGXCGPWGSUMNI-BVHTXILBSA-N 5(S),15(S)-DiHETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O UXGXCGPWGSUMNI-BVHTXILBSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NNPWRKSGORGTIM-HCCKYKKOSA-N 8(S),15(S)-DiHETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/[C@@H](O)C\C=C/CCCC(O)=O NNPWRKSGORGTIM-HCCKYKKOSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- PWAACAMQKVIVPZ-UHFFFAOYSA-N Corylin Natural products OC1=CC=C2C(=O)C(C3=CC=C4OC(C=CC4=C3)(C)C)=COC2=C1 PWAACAMQKVIVPZ-UHFFFAOYSA-N 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010060902 Diffuse alveolar damage Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100032052 Elongation of very long chain fatty acids protein 5 Human genes 0.000 description 1
- 241001433703 Escherichia coli O111:B4 Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010058732 Fatty Acid Elongases Proteins 0.000 description 1
- 102000036181 Fatty Acid Elongases Human genes 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000204888 Geobacter sp. Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 description 1
- 101710119050 Glutathione peroxidase 1 Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010018713 Gravitational oedema Diseases 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101000921361 Homo sapiens Elongation of very long chain fatty acids protein 5 Proteins 0.000 description 1
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
- 101001064864 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX12 Proteins 0.000 description 1
- 101001064853 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 101710156627 Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
- 102100031949 Polyunsaturated fatty acid lipoxygenase ALOX12 Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010051739 Pulmonary sepsis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 101150031809 cox1/2 gene Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002121 epoxyeicosatrienoic acids Chemical class 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 208000018634 fetal akinesia deformation sequence Diseases 0.000 description 1
- 208000012165 fetal akinesia deformation sequence syndrome Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000002421 fluorescence-activated droplet sorting Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- UXVRTOKOJOMENI-WLPVFMORSA-N lipoxin B4 Chemical compound CCCCC[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-WLPVFMORSA-N 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012337 thromboprophylaxis Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 1
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 1
- 235000008209 xanthohumol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Arachidonic acid is an n-6 essential polyunsaturated fatty acid (PUFA) present in the human diet. It is an essential PUFA and a building block for phospholipids found in cellular membranes including neuronal cell membranes and neuronal organelles such as the mitochondria and the endoplasmic reticulum, where it is the dominant PUFA.
- the structure of arachidonic acid includes four double bonds in a 1,4-polyene configuration resulting in three bis-allylic positions and two mono-allylic positions that flank both ends of this configuration. The following structure provides an example of mono-allylic and bis-allylic positions in a 1,4-diene system.
- Arachidonic acid is readily oxidized at the bis-allylic sites either as a substrate of several enzymes (COX1, COX2, various LOX enzymes, and cytochromes P450, etc.) yielding multiple pro-inflammatory and pro-thrombotic eicosanoid mediators such as prostaglandins, leukotrienes and thromboxanes, or by reactive oxygen species (ROS) leading to further pro-inflammatory metabolites. In either case, such oxidation leads to inflammation in all tissues affected, including the lungs.
- COX1, COX2, various LOX enzymes, and cytochromes P450, etc. multiple pro-inflammatory and pro-thrombotic eicosanoid mediators such as prostaglandins, leukotrienes and thromboxanes, or by reactive oxygen species (ROS) leading to further pro-inflammatory metabolites.
- ROS reactive oxygen species
- the pro-inflammatory and pro-thrombotic eicosanoid mediators then initiate further inflammatory cascades.
- Arachidonic acid s role in enzymatic generation of pro-inflammatory mediators is an important property of this PUFA. Indeed, replacing a portion of arachidonic acid in cell membranes by consuming fish rich in long chain n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, has been reported to decrease inflammation merely by a mass balance approach. See, e.g., Calder, Biochem. Soc. Trans., 33(part 2):423-427 (2005).
- Oxidative processes involving arachidonic acid are a key component in the generation of inflammatory processes in vivo.
- chronic inflammation has deleterious impacts on patients.
- the presence of chronic vascular inflammation has been implicated as a causative factor in coronary artery disease.
- chronic arthritic conditions are associated with varying levels of pain, and disfigurement (especially in fingers) is also due to uncontrolled and chronic inflammatory processes.
- TNF-alpha blockers Chronic pain associated with arthritis can be controlled in many cases with monoclonal antibodies such as TNF-alpha blockers.
- these antibodies carry substantial risks such as invasive fungal, bacterial, and viral infections, as well as lymphoma and other malignancies, some fatal, especially in children and adolescent patients. In many patients, such risks are unacceptable.
- compositions and methods for controlling chronic inflammation in a patient employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes.
- D6-AA has a long half-life such that when a therapeutic concentration is reached, the patient will experience long term control of chronic inflammatory process and long term control of the chronic pain.
- a method for controlling chronic inflammation in a patient comprises administering an effective amount of a composition comprising D6-AA to said patient for an effective period of time such that the accumulated D6-AA in the cellular membranes attenuates the inflammatory process, thereby controlling the chronic inflammation in the patient.
- a method for controlling chronic inflammation in a patient provides relief from chronic pain associated with the chronic inflammation.
- the methods described herein comprise a composition designated as D6-AA which composition comprises D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites have been replaced by deuterium atoms.
- D6-AA which composition comprises D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites have been replaced by deuterium atoms.
- a pharmaceutical composition comprising a pharmaceutically acceptable excipient and from about 10 mg to about 2,000 mg of a composition of D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, has no more than about 30% of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
- the chronic inflammation is vascular inflammation.
- the chronic inflammation is inflammation associated with arthritis.
- the arthritis is rheumatoid arthritis.
- the arthritis is osteoarthritis.
- the chronic inflammation is neuroinflammation.
- the chronic inflammation is associated with a neurodegenerative disease.
- FIG. 1 Different bis-allylic sites may play a different role in oxidation of arachidonic acid.
- FIG. 2 Bis-allylic site-specific isotopically modified arachidonic acids.
- the bis-allylic positions are located at the C7, C10, and C13 positions.
- “D” represents deuterium.
- FIGS. 3 - 6 Groups of female (f) and male (m) mice received a 6-week course of dietary (H) AA or a 6-week course of deuterated arachidonic acid (D6-ARA, 15 mg/day) followed by single intranasal administration of LPS. Control mice (norm) did not receive the single intranasal administration of LPS.
- Mice that received dietary AA showed an increase of the alveolar lumen area ( FIG. 3 is the median; FIG. 4 is the average) and an increase of the interalveolar septa thickness ( FIG. 5 is the median; FIG. 6 is the average), which is likely associated with stronger edema and inflammatory infiltration.
- mice that received D6-ARA exhibited alveolar lumen area and thickness consistent with controls.
- the data of FIGS. 3 - 6 indicate a lesser degree of inflammatory lesion of the lungs after course of D-form compared to H-form.
- Preliminary data indicates that D6-ARA had the best protective effect as compared to other deuterated PUFAs.
- FIGS. 7 A-D show various molecules and reactions relating to PUFAs.
- FIG. 7 A shows various PUFAs.
- FIG. 7 B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen.
- FIG. 7 C shows multiple products of non-enzymatic lipid peroxidation (LPO).
- FIG. 7 D shows numerous products of enzymatic arachidonic acid oxidation.
- FIG. 8 shows the thickness of interalveolar septa of BALB/c mice treated with PUFAs.
- FIGS. 9 A- 9 C shows deuterated arachidonic acid as a % of all arachidonic acid at eight weeks dosing and washout over the subsequent 9 weeks with H-AA feeding.
- FIG. 9 A shows the graphs for visceral organs and skin.
- FIG. 9 B shows graphs for neural tissue: whole brains and whole eyes.
- FIG. 9 C shows lung arachidonic acid and conversion to longer chain PUFAs.
- FIGS. 10 A-C show histological evaluation of the effect of intranasal administration of lipopolysaccharide on the lungs of treated male mice.
- FIG. 11 shows graphs of the thickness of interalveolar septa.
- the inflammation is due to intracellular accumulation of pro-inflammatory oxidized PUFA products.
- the term “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
- the term “about” when used with regard to a dose amount means that the dose may vary by +/- 10%.
- compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
- compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose.
- a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
- D6-arachidonic acid or “D6- AA” means a composition that comprises, on average, at least about 4.8 to about 7.2 deuterium atoms in the arachidonic acid (excluding the ester portion thereof if employed). In one embodiment, this includes 7,7,10,10,13,13-D6-arachidonic acid or esters thereof. In another embodiment, this includes compositions of deuterated arachidonic acid or ester thereof that comprises, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.
- the amount of deuterium replacing hydrogen at the bis-allylic sites (7, 10 and 13) and at the mono-allylic sites (4 and 16) of arachidonic acid can be any one of the following (all percentages are on an average basis): at least about 85% deuterium at bis-allylic sites / no more than about 30% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 25% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 20% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 10% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 5% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 30% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 25% at mono-allylic
- an ester thereof refers to a C1-C6 alkyl esters, glycerol esters (including monoglycerides, diglycerides and triglycerides), sucrose esters, phosphate esters, and the like.
- the particular ester group employed is not critical provided that the ester is pharmaceutically acceptable (non-toxic and biocompatible).
- the ester is a C1-C6 alkyl ester which is preferably an ethyl ester.
- phospholipid refers to any and all phospholipids that are components of the cell membrane or other lipid membrane(s) within a cell. Included within this term are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin. In the motor neurons, the cell membrane is enriched in phospholipids comprising arachidonic acid.
- bis-allylic site refers to the methylene group (CH 2 ) separating two double bonds as depicted above.
- mono-allylic site refers to the methylene group having an adjacent neighboring double bond on one side and a further methylene group on the opposite side as depicted above.
- cellular component refers to any relevant structure found in human cells, including organelles having a lipid or phospholipid wall. Examples of such cellular components include, by way of example only, the mitochondria, the endoplasmic reticulum, golgi apparatus, nuclear membrane, and the like. Cellular components also include the cell membrane (plasma membrane).
- regulatory enzymes as it relates to the neutralization of oxidized arachidonic acid products refer to those enzymes that are responsible to remove, alter, or destroy one or more of the oxidized arachidonic acid products from the cells to prevent the accumulation of these oxidized products within the cell.
- regulatory enzymes include glutathione peroxidase (GPx) enzymes, particularly GPx4. When these enzymes are impaired, such impairment results in the accumulation of lipid peroxides leading to loss of functionality, which is often death followed by cell death.
- GPx glutathione peroxidase
- oxidized PUFA products refer to any oxidized form of a polyunsaturated fatty acid as well as any and all metabolites formed from the oxidized PUFA including reactive aldehydes, ketones, alcohols, carboxyl derivatives which are either pro-inflammatory metabolites or are precursors of pro-inflammatory metabolites.
- neutralization of oxidized products refers to enzymatic processes that remove, alter, or destroy toxic oxidized PUFA products from the cells to prevent the accumulation of these oxidized products within the cell. In healthy individuals, the neutralization of the oxidized PUFA products prevents accumulation of these products thereby assuring that dysfunctionality of cells especially neurodegenerative cells is controlled.
- pathology of a disease refers to the cause, development, structural/functional changes, and natural history associated with that disease. Included in the pathology of the disease is the reduction in cellular functionality.
- natural history means the progression of the disease in the absence of treatment per the methods described herein, for example, prior to the commencement of treatment as described herein.
- chronic inflammation refers to known conditions where inflammation plays a key role in the development and progression of chronic diseases including, but not limited to, autoimmune diseases, neurodegenerative diseases, metabolic disorders such as atherosclerosis and obesity, fibrosis, and cancer to name a few.
- Such diseases also include asthma, arthritis including rheumatoid arthritis, juvenile chronic arthritis, osteoarthritis, myossitis, Crohn’s disease, gastritis, colitis, ulcerative colitis, inflammatory bowel disease, proctitis, pelvic inflammatory disease, systemic lupus, erythematosus, rhinitis, conjunctivitis, scleritis, chronic inflammatory polyneuropathy, Lyme’s disease, psoriasis, dermatitis, and eczema, neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis to name a few.
- Such diseases are deemed chronic as the condition involved is either lifelong (after diagnosis) such as autoimmune diseases or which take substantially long periods of time to treat and resolve such as obesity.
- control or “controlling” as it relates to chronic inflammation means that the extent of inflammation arising from a chronic disease has been decreased or attenuated over time such that the degree of discomfort or pain arising in the patient is reduced. While the level of discomfort felt by a patient is personal and distinct from other patients suffering through the same disease, the decrease in inflammation can be measured by the extent of swelling, a decrease in C Reactive Protein (CRP), and other standards well known in the art. Preferably, a decrease of at least 15% and preferably at least 35% in CRP concentrations between start of therapy and 45 days or 90 days post start of therapy evidence control of the inflammation.
- CRP C Reactive Protein
- terapéutica concentration means an in vivo concentration of a deuterated arachidonic acid that controls chronic inflammation.
- a concentration of D6-AA in red blood cells of at least about 1% and preferably at least from about 1.5% to about 6% based on the total amount of arachidonic acid found therein (including deuterated arachidonic acid) will be therapeutic.
- the term “patient” refers to a human patient or a cohort of human patients suffering from a neurodegenerative disease treatable by administration of a prodrug of deuterated arachidonic acid.
- the term “pharmaceutically acceptable salts” of compounds disclosed herein are within the scope of the methods described herein and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
- pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
- inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
- organic acids e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, ox
- the compound When the compound has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca2 + , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g., arginine, lysine, and ornithine).
- metals such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca2 + , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanol
- inflammation-related disorders represent a heterogeneous group of diseases that have a common underlying inflammatory pathology.
- inflammation-related disorders include, but are not limited to, asthma, rheumatoid arthritis, juvenile chronic arthritis, osteoarthritis, myositis, Crohn’s disease, gastritis, colitis, ulcerative colitis, inflammatory bowel disease, proctitis, pelvic inflammatory disease, systemic lupus erythematosus, rhinitis, conjunctivitis, scleritis, chronic inflammatory polyneuropathy, Lyme disease, psoriasis, dermatitis, eczema, autoimmune disorders, neurodegenerative disorders, and atherosclerosis.
- Inflammation-related disorders often involve increased generation of ROS (reactive oxygen species) and lipid processing abnormalities (Winyard PG et al. Free radicals and inflammation. Burkhauser, Basel, 2000; Filippo et al., Journal of Alzheimer’s Disease (2010) ; 20, S369-S379).
- ROS reactive oxygen species
- lipid processing abnormalities Winyard PG et al. Free radicals and inflammation. Burkhauser, Basel, 2000; Filippo et al., Journal of Alzheimer’s Disease (2010) ; 20, S369-S379).
- the combination of ROS and lipid processing abnormalities leads to increased PUFA peroxidation that generates toxic reactive carbonyl compounds which inflict further damage at numerous other sites within the cell (Negre-Salvayre A et al., Br J Pharmacol 2008;153:6-20). Consequently, the detection of oxidatively damaged biomolecules and the presence of ROS in inflammatory states both implicate elevated oxidative stress levels.
- Lipid peroxidation is important in atherosclerosis and in worsening of initial tissue injury caused by ischemic or traumatic brain damage.
- Atherosclerosis is a lipid storage disorder associated with inflammatory response (Ross R, New Engl J Med. 1999;340:115-127).
- Oxidation of PUFA-rich low-density lipoprotein (LDL) was suggested to be a major risk factor for atherosclerosis and for hypertension associated with atherosclerosis.
- Angiotensin II (Ang-II) is involved in this process, enhancing macrophage lipid peroxidation both in vivo and in vitro (Keidar S. Life Sci. 1998;63: 1-11).
- Ang-II Angiotensin II
- Rheumatoid arthritis may be associated with inflammation and PUFA peroxidation through a reperfusion injury mechanism.
- the synovial cavity normally has a negative pressure.
- vascular patency is maintained, allowing for nutrition of the avascular cartilage.
- the cavity pressure is raised and upon movement this pressure exceeds the capillary perfusion pressure, causing collapse of the blood vessels.
- ROS reactive oxygen species
- IgG inducing rheumatoid factor production
- Hyaluronan leading to hyaluronan fragmentation products which may alter immune function
- PUFAs generating reactive carbonyls which alter T cell/macrophage interactions
- lipoproteins leading to the production of monocyte chemotactic peptides.
- Progressive hypoxia alters immune function, predominantly by calcium mediated pathways.
- PUFA peroxidation products including, but not limited to, conjugated dienes, isoprostanes and reactive aldehydes such as HNE are detectable in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis patients (Selley ML Annals Rheum Disease 1992;51:481-484).
- Oxidative damage is implicated in a wide variety of diseases such as mitochondrial diseases, neurodegenerative diseases, neurodegenerative muscle diseases, retinal diseases, energy processing disorders, kidney diseases, hepatic diseases, lipidemias, cardiac diseases, inflammation, and genetic disorders.
- Oxidative stress at sites with chronic inflammation can also cause genetic changes.
- Reactive carbonyl products of PUFA peroxidation can react with DNA bases and change their complementarity pattern (Esterbauer H et al., Free Rad Biol Med 1991;11:81-128).
- the development of mutations in the p53 tumor suppressor gene and other key regulatory genes can convert inflammation into chronic disease in rheumatoid arthritis and other inflammatory disorders (Tak PP et al., Immunology Today 2000;21:78-82).
- ROS reactive oxygen species
- Oxidative damage can be relayed to other biomolecules within the cell, such as DNA and proteins, through direct and indirect contact with activated oxygen, oxidized membrane constituents, or other oxidized cellular components.
- biomolecules within the cell such as DNA and proteins
- activated oxygen oxygen, oxidized membrane constituents, or other oxidized cellular components.
- oxidative damage may propagate throughout a cell give the mobility of internal constituents and the interconnectedness of cellular pathways.
- PUFAs endow mitochondrial membranes with appropriate fluidity necessary for optimal oxidative phosphorylation performance.
- PUFAs also play an important role in initiation and propagation of the oxidative stress.
- PUFAs react with ROS through a chain reaction that amplifies an original event (Sun M, Salomon RG, J. Am. Chem. Soc. 2004; 126:5699-5708).
- ROS ROS
- nonenzymatic formation of high levels of lipid hydroperoxides is known to result in several detrimental changes.
- Coenzyme Q10 has been linked to increased PUFA toxicity via PUFA peroxidation and the toxicity of the resulting products (Do TQ et al., PNAS USA 1996; 93:7534-7539).
- oxidized products negatively affect the fluidity and permeability of their membranes; they lead to oxidation of membrane proteins; and they can be converted into a large number of highly reactive carbonyl compounds.
- the latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al., Brit. J. Pharmacol. 2008; 153 :6-20).
- alpha, beta-unsaturated aldehydes such as 4-hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), 4-hydroxyhex-2-enal (4-HHE; formed from n-3 PUFAs like ALA or DHA), and corresponding ketoaldehydes (Esterfbauer H, et al., Free Rad. Biol. Med. 1991; 11:81-128; Long EK, Picklo MJ. Free Rad. Biol. Med. 2010; 49:1-8).
- PUFAs cross-link (bio)molecules through Michael addition or Schiff base formation pathways and have been implicated in a large number of pathological processes (such as those introduced above), age-related and oxidative stress-related conditions, and aging.
- PUFAs appear to oxidize at specific sites because methylene groups of 1,4-diene systems (the bis-allylic position) are substantially less stable to ROS, and to enzymes such as cyclooxygenases, cytochromes and lipoxygenases, than allylic methylenes.
- Eicosanoids are important cell signaling molecules involved in an array of physiological and pathological processes, including various immune responses such as promoting inflammation, inhibiting inflammation, allergy, and fever. There are multiple oxidative and immune response related pathways in the biosynthesis of eicosanoids from arachidonic acid.
- the enzyme 5-lipoxygenase (5-LO or ALOX5) converts arachidonic acid (ARA) into 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene A4 (LTA4), which is then converted into different leukotrienes (LTC4, LTD4, and LTE4) by downstream enzymes.
- LTC4, LTD4, and LTE4 are potent bronchoconstrictors and stimulators of mucus secretion in lung tissue and are known to promote hypersensitivity reactions in respiratory conditions such as asthma.
- 15-lipoxygenase 15-lipoxygenase 1, 15-LOX, 15-LOX1, or ALOX15
- 12-lipoxygenase (12-LOX or ALOX12) metabolize arachidonic acid to form 15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HPETE) and 12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HPETE).
- Both 15(S)-HPETE and 12(S)-HPETE are further reduced by cellular glutathione peroxidase to their corresponding hydroxy analogs, 15-hydroxyicosatetraenoic acid (15(S)-HETE) and 12-hydroxyeicosatetraenoic acid (12(S)-HETE), respectively.
- 15(S)-HPETE and 15(S)-HETE are further metabolized to various bioactive products such as lipoxins, hepoxillins, eoxins, 8(S),15(S)-diHETE, 5(S), 15(S)-diHETE and 15-oxo-eicosatetraenoic acid (15-oxo-ETE).
- the 12/15-lipoxygenase metabolities have been shown to have both pro- and anti-inflammatory properties.
- COX1 and COX2 (also known as prostaglandin-endoperoxide synthase-1 (PTGS1) and PTGS2, respectively) initiates metabolization of arachidonic acid to a subclass of eicosanoids that includes prostaglandins (such as prostacyclins), and thromboxanes.
- Prostaglandins are mediators of inflammatory and anaphylactic reactions and thromboxanes are mediators of vasoconstriction and platelet aggregation, playing a major role in blood clotting.
- cytochrome P450 enzymes metabolize arachidonic acid to EETs (epoxyeicosatrienoic acids).
- EETs can promote the active termination of inflammation through mediating a broad array of anti-inflammatory and pro-resolving mechanisms.
- compositions comprising bis-allylic isotopically modified essential PUFAs, including arachidonic acid, can inhibit inflammation in vivo, which is important given the multiple metabolic pathways involving arachidonic acid and the potential pro- and anti-inflammatory effects resulting therefrom.
- the purified enzymatic study Choistyakov et al.
- the cell assay vanratil et al.
- LPO lipid peroxidation
- This pro-inflammatory non-enzymatic component is impervious to antioxidant approaches due to the structural aspects of the lipid bilayers making up membranes Inflammation associated LPO can be initiated through various mechanisms. (Zhang et al., Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation, J Blot Chem 2002 doi: 10.1074/jbc.M209124200).
- Arachidonic acid is readily oxidized at the bis-allylic sites either as a substrate of several enzymes (COX1, COX2, various LOX enzymes, and cytochromes P450, etc.) yielding multiple pro-inflammatory and pro-thrombotic eicosanoid mediators such as prostaglandins, leukotrienes and thromboxanes, which then initiate further inflammatory cascades. Additionally, oxidation can occur via reaction with reactive oxygen species (ROS) leading to further pro-inflammatory metabolites. In either case, such oxidation leads to inflammation in all tissues affected, including the lungs.
- ROS reactive oxygen species
- ROS reactive oxygen species
- LPO lipid membranes
- COX and LOX inhibitors can be employed to down-regulate this process, with various efficacy.
- the methods of the present disclosure rely on deuteration of the three oxidation prone sites within PUFA molecules, to substantially slow down the rate limiting step of oxidation (both enzymatic and non-enzymatic) via the isotope effect (IE).
- IE isotope effect
- D-PUFAs were tested in a lipopolysaccharide (LPS)-inflicted lung inflammation model in mice, a well-known lung inflammation model. (See Example 1.)
- LPS lipopolysaccharide
- ALI human acute lung injury
- the end results are microvascular injury and diffuse alveolar damage with intrapulmonary hemorrhage, edema, and fibrin deposition (Johnson and Ward, J. Clin. Invest., (1974), 54:349-357; Flierl et al., Med.
- the D-PUFAs of the disclosure are administered to break the inflammatory cascade of specific cytokines and chemokines known to induce and amplify lung inflammation.
- MCP-1 monocyte chemoattractant protein
- TNF-a tumor necrosis factor alpha
- the pro-inflammatory and pro-thrombotic eicosanoid mediators then initiate further inflammatory cascades.
- Arachidonic acid s role in enzymatic generation of pro-inflammatory mediators is an important property of this PUFA. Indeed, replacing a portion of arachidonic acid in cell membranes by consuming fish rich in long chain n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, has been reported to decrease inflammation merely by a mass balance approach. See, e.g., Calder, Biochem. Soc. Trans. , 33(part 2):423-427 (2005).
- Oxidative processes involving arachidonic acid are a key component in the generation of inflammatory processes in vivo.
- chronic inflammation has deleterious impacts on patients.
- the presence of chronic vascular inflammation has been implicated as a causative factor in coronary artery disease.
- chronic arthritic conditions are associated with varying levels of pain, and disfigurement (especially in fingers) is also due to uncontrolled and chronic inflammatory processes.
- the resulting pathology of chronic inflammatory diseases differs from the underlying etiology of the disease. That is to say that whatever divergent conditions trigger each of these diseases (the etiology), once triggered the pathology of these diseases involves the accumulation of pro-inflammatory oxidized PUFA products that are pro-inflammatory metabolites or are precursors to pro-inflammatory metabolites. As the amounts of oxidized products increases, the extent of the inflammatory response increases as such oxidized PUFA products activate the biological cascade leading to inflammation.
- the increasing concentration of oxidized PUFA products in cells correlates with the progression of the chronic disease that impacts these cells.
- the methods described herein provide for in vivo delivery of deuterated arachidonic acid to these cells, thereby limiting the amount of oxidized PUFA products generated as both LPO and enzymatic oxidation of arachidonic acid are reduced.
- these two mechanisms either alone or in combination create oxidative stress on the cell. Reduction in the oxidative stress has a positive impact on treating the disease as well as the underlying inflammation.
- the composition of this invention attenuates both the inflammatory component of the disease as well as addresses the underlying disease itself.
- the origin of the oxidative stress varies due to differences in the underlying etiology but typically involve one or more different reactive oxygen species. Regardless of the differences in etiology, the production of oxidized PUFA products evidences an imbalance between routine production and detoxification (neutralization) of these oxidized products.
- the lipid membrane of the cell as well as that of the endoplasmic reticulum and mitochondria of neurons comprise arachidonic acid (a 20-carbon chain polyunsaturated fatty acid (“PUFA”) having 4 sites of cis-unsaturation). Separating each of these 4 sites are 3 bis-allylic methylene groups. These groups are particularly susceptible to oxidative damage as compared to allylic methylene and methylene groups. Apart from leading to further membrane damage, oxidation of arachidonic acid reduces the local concentration of arachidonic acid and must be replaced. Thus, it is a double hit: a positive bioactive membrane component is converted to a toxic membrane component.
- the latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al., Brit. J. Pharmacol. 2008 ; 153:6-20).
- oxidized PUFA product(s) The most prominent products of arachidonic acid oxidation are alpha, beta-unsaturated aldehydes such as 4-hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), and corresponding ketoaldehydes (Esterfbauer H, et al., Free Rad. Biol. Med. 1991; 11:81-128). As noted above, these reactive carbonyls cross-link (bio)molecules through Michael addition or Schiff base formation pathways, continuing the underlying pathology of the disease. Each of these metabolites derived from oxidized PUFAs are encompassed by the term “oxidized PUFA product(s).”
- CRP C-reactive protein
- CK Creatine Kinase
- CK-BB brain
- CK-MB CK-MB
- CK-MM skeletal muscle
- the progression of a chronic inflammatory disease correlates with the increase in oxidative stress in the cell including the accumulation of oxidized PUFAs.
- Therapeutic intervention as per the methods described herein limits further increases in oxidative stress and then reduces these levels to control the inflammation associated therewith.
- the examples provided below illustrate the significant reduction of inflammation achieved by D6-AA.
- the chronic inflammation is vascular inflammation.
- the chronic inflammation is inflammation associated with arthritis.
- the arthritis is rheumatoid arthritis.
- the arthritis is osteoarthritis.
- the chronic inflammation is neuroinflammation.
- Deuterated arachidonic acid is known in the art.
- 7,7,10,10,13,13-D6-arachidonic acid is disclosed by Shchepinov, et al., Molecules, 28(12):31 et seq. (2016).
- catalytic deuteration of arachidonic acid using a ruthenium catalyst resulting in about 80% or more deuteration of the bis-allylic sites and about 30% or less deuteration at the mono-allylic sites is disclosed by Shchepinov, et al., U.S. Pat. No. 10,730,821. Both of these references are incorporated herein by reference in their entirety.
- other deuterated arachidonic acid compounds are known in the art. Conversion of each of these PUFAs into the corresponding esters are well known in the art.
- the methods described herein comprise the administration of D6-AA or an ester thereof to a patient suffering from a chronic inflammatory disease.
- the D6-AA slowly accumulates in the cells of the body including those that are subject to chronic inflammation.
- the clinician can monitor the progress of the therapy by measuring the amount of C-reactive protein (CRP) in the patient as chronic inflammatory diseases generate higher CRP levels and a reduction in that inflammation corresponds to a reduction in the CRP levels.
- CRP C-reactive protein
- the clinician can correlate lower CRP levels with increasing concentrations of D6-AA in red blood cells over time. As the concentration of D6-AA in red blood cells increases, CRP levels are expected to fall.
- a method for reducing inflammation of a chronic inflammatory disease in an adult patient comprising periodically administering D6-AA or an ester thereof to the patient with a dosing regimen that comprises a primer dose and a maintenance dose.
- the primer dose comprises periodic administration of deuterated arachidonic acid or an ester thereof. In an embodiment, the primer dose comprises at least about 10 milligrams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 10 milligrams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 0.10 grams to about 1 gram. In an embodiment, the primer dose is continued for about 15 to about 50 days or from about 30 days to about 45 days, e.g., to rapidly achieve a therapeutic concentration of deuterated arachidonic acid in vivo, thereby reducing the rate of disease progression.
- the maintenance dose is periodically administered. In an embodiment, no more than about 65% of the loading dose of the deuterated arachidonic acid or an ester thereof per day is administered as a maintenance dose. In an embodiment, the maintenance dose is utilized to ensure that the therapeutic concentration of deuterated arachidonic acid is maintained in vivo such that a reduced rate of disease progression is maintained.
- said periodic administration of the loading dose comprises administration of from about 0.05 grams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In some embodiments, the loading dose is from about 0.05 grams to about 1.5 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1.5 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1.25 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1 gram per day. In some embodiments, the loading dose is from about 0.10 grams to about 0.5 grams per day.
- the loading dose may be any value or subrange within the recited ranges, including endpoints.
- the loading dose is administered for at least 5 days per week, and preferably 7 days a week.
- the periodic administration of the maintenance dose of deuterated arachidonic acid or an ester thereof per day comprises no more than 65% or no more than 55% of the loading dose.
- the maintenance dose is administered per day, or at least 5 days per week, or at least once per week, or at least once per month.
- the maintenance dose comprises no more than 35% of the loading dose which is administered at least once a month.
- the periodic administration of the maintenance dose is calibrated to be an amount of D6-AA or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
- the loading dose is administered for between about one month and about 4 months. In some embodiments, the loading dose is administered for between about 1 month and about 2 months. In some embodiments, the loading dose is administered for about 1 month.
- the length of time may be any value or subrange within the recited ranges, including endpoints.
- the loading dose is administered between meals. In some embodiments, the dosing is done with food, e.g. during meals.
- whether the patient has a therapeutic level of D6-AA incorporated into the patient’s cells is determined by simply measuring the patient’s CRP levels. In some embodiments, the amount of D6-AA is determined based its concentration in red blood cells. In the event that the clinician determines that the patient is not responding as well as the clinician expected, an increase in either the loading dose or the maintenance dose can be made.
- whether the patient has a therapeutic level of deuterated arachidonic acid incorporated into the patient’s neurons is determined.
- the level of deuterated arachidonic acid is determined based on the amount of deuterated arachidonic acid in the patient’s red blood cells.
- the therapeutic target is at least about 6% or at least about 12% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is at least about 15%. In some embodiments, the therapeutic target is at least about 20%.
- the therapeutic target is between about 12% and about 30% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is between about 12% and about 25% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is between about 12% and about 20% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample).
- the therapeutic target is between about 15% and 25% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells. In some embodiments, the therapeutic target is between about 15% and about 20% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). The amount may be any value or subrange within the recited ranges, including endpoints.
- D6-AA or an ester thereof may be administered using any dosing regimen.
- D6-AA or an ester thereof may be administered daily, every two days, every 3 days, etc.
- D6-AA or an ester thereof may be administered for a first period of time (e.g., one week, 2 weeks, 3 weeks, 4 weeks or more), followed by a period of time where no D6-AA or an ester thereof is administered (e.g., 1 day, 2 days, 1 week or more).
- D6-AA or an ester thereof may be administered for a period of time until the therapeutic level is reached, and then administered less frequently.
- D6-AA or an ester thereof may be administered daily until the therapeutic level is reached, and then administered every 2, 3, 4, 5, 6, or 7 days, or longer, to maintain the therapeutic level.
- D6-AA or an ester thereof can be used alone.
- D6-AA or ester thereof can be combined with 11,11-D2-linoleic acid or an ester thereof and/or with 8,8,11,1 1-D4-linoleic acid or an ester thereof.
- a portion of the 11,11-D2-lineoleic acid is converted to 13,13-D2-arachidonic acid and a portion of the 8,8,11,11-D4-linoleic acid is converted to 10,10,13,13-D4-arachidonic acid.
- a combination therapy can employ a drug that operates via an orthogonal mechanism of action relative to the methods described herein.
- Suitable drugs for use in combination include, but not limited to, antioxidants such as edaravone, idebenone, mitoquinone, mitoquinol, vitamin C, or vitamin E, provided that none of these antioxidants interfere with the therapeutic action of the deuterated linoleic acid or ester thereof.
- D6-AA or ester thereof is accomplished by any number of accepted modes of administration.
- the actual amount of the drug used in a daily or periodic dose per the methods of this invention, i.e., the active ingredient, is described in detail above.
- the drug can be administered at least once a day, preferably once or twice or three times a day.
- compositions of this invention will be administered as pharmaceutical compositions by any of a number of known routes of administration. However, orally delivery is preferred typically using tablets, pills, capsules, and the like.
- the particular form used for oral delivery is not critical but due to the large amount of drug to be administered, a daily or periodic unit dose is preferably divided into subunits having a number of tablets, pills, capsules, and the like.
- compositions as disclosed herein may be manufactured by any of the methods well-known in the art, such as, by conventional mixing, tableting, encapsulating, and the like.
- the compositions as disclosed herein can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
- compositions can comprise the drug in combination with at least one pharmaceutically acceptable excipient.
- Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds.
- excipient may be any solid, liquid, or semi-solid that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- compositions as disclosed herein may, if desired, be presented in a pack or dispenser device each containing a daily or periodic unit dosage containing the drug in the required number of subunits.
- a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, a vial, or any other type of containment.
- the pack or dispenser device may be accompanied by instructions for administration including, for example, instructions to take all of the subunits constituting the daily or periodic dose contained therein.
- the amount of the drug in a formulation can vary depending on the number of subunits required for the daily or periodic dose of the drug.
- the formulation will contain, on a weight percent (wt. %) basis, from about 10 to 99 wt. % of the drug based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 50 to 99 wt. %.
- the drug is encapsulated in a capsule without the need for any excipients such as stabilizers, antioxidants, colorants, etc. This minimizes the number of capsules required per day by maximizing the volume of drug in each capsule.
- H-AA Non-deuterated arachidonic acid (only with the natural abundance of deuterium)
- H-LA Non-deuterated linoleic acid (only with the natural abundance of deuterium)
- D2-AA 11,11-D2-Arachidonic Acid
- kg kilograms
- LPS lipopolysaccharide
- D2-LA 11,11-D2-Linoleic Acid (aka “drug”)
- LA Linoleic Acid
- LPO Lipid peroxidation
- LPS administration is known to promote inflammation through various mechanisms including secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS.
- This example employed LPS to ascertain the extent of inflammation arising from ROS induced oxidation of H-AA versus D-AA in the lungs of mice.
- the first group was control mice treated with H-LA control mice.
- the second group of mice received a 6-week course of D-LA. It is understood that in vivo conversion of a portion of both H-LA and D-LA occurs to provide for AA and 13,13-D2-AA respectively.
- the third group of mice received a 6-week course of H-AA.
- the fourth group of mice received a 6-week course of D-AA.
- mice treated with D-LA had almost a 60% reduction in the same spatial distance evidencing the benefits of D-AA in treating inflammation.
- LPS administration was conducted as per Example 1 above except that four groups of mice were used. The first two groups (1 and 2) were control mice (male and female). The next two groups (3 and 4) of mice received a 6-week course of H-AA (male and female). Finally, the last two groups (5 and 6) of mice received a 6-week course of D6-AA (second group). Groups 3, 4, 5 and 6 then received a single intranasal administration of LPS to induce acute lung inflammation. The degree of the inflammatory response was determined per Example 1. The results of this experiment are set forth in Table 2.
- Examples 1a, 2a, and 3a represent a more complete recitation of Examples 1, 2, and 3 respectively.
- Example 1a Administration of D-AA in a Mouse Model of Lung Inflammation
- LPS treatment promotes inflammation through various mechanisms including secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS.
- an acute lung inflammation quickly follows.
- mice receiving a 6-week course of dietary (H) AA followed by single intranasal administration of LPS the thickness of the interalveolar septa was significantly increased, which is likely associated with stronger edema and inflammatory infiltration.
- Such a pronounced inflammatory infiltration of the interalveolar septa contributed to their destruction and more frequent formation of emphysema foci in this group.
- mice that received the D-form were characterized by decrease in alveoli lumens, which may be associated with a lower (compared with the H-form) frequency of emphysematous transformation of the lungs. (See FIGS. 3 - 6 .)
- e-selectin also named Endothelial Leukocyte Adhesion Molecule or ELAM
- CRP C-reactive protein
- activated endothelial cells are created by adding known activators such as lipopolysaccharides, TNF, or IL-1(3 to rat intestinal MVEC cells.
- Activated cells are incubated with an isotopically modified PUFA such as a deuterated PUFA (“D-PUFA”) (0.01, 0.1, 1.0, 10.0, or 100 ⁇ M of D-PUFA and 1:1 or different ratio combinations of D-PUFA mixtures, e.g. D2-LA, D4-ALA, et al., see e.g.
- D-PUFA deuterated PUFA
- H-PUFA means not deuterated or tritiated (0.01, 0.1, 1.0, 10.0, or 100 ⁇ M of LA, ALA, et al., and corresponding ratio combinations of non-deuterated mixtures) for 24, 48, and 72 hours.
- Activated cells are known to produce ELAM, which can be measured using, for example, an E-selectin monoclonal antibody-based ELISA assay.
- D-PUFA treated cells are expected to produce lower amounts of ELAM as compared to cells treated with H-PUFA.
- a CRP assay can be used to measure the in vitro activity of test compounds in reducing expression of CRP in Human Hep3B epithelial cells.
- activated epithelial cells are created by adding known activators such as lipopolysaccharides, TNF, or IL-1(3 to Human Hep3B epithelial cells.
- Activated cells are incubated with D-PUFA (0.01, 0.1, 1.0, 10.0, or 100 ⁇ M), and different ratio combinations of different D-PUFAs) or H-PUFA (0.01, 0.1, 1.0, 10.0, or 100 ⁇ M of LA, ALA, and corresponding combinations of H-PUFAs) for 24, 48, and 72 hours.
- D-PUFA treated cells are expected to produce lower amounts of CRP as compared to cells treated with H-PUFA.
- Carrageenan-Induced Paw Edema is a model of inflammation that measures time-dependent edema formation following carrageenan administration into the intraplantar surface of a rat paw.
- D-PUFA see, e.g., species of Formula (1)
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- Rats are lightly anaesthetized under isofluorane and receive a subplantar injection of 50 ⁇ L saline containing 1% w/v carrageenan.
- Paw volumes are determined using a water plethysmometer and compared to paw volume prior to carrageenan administration. Volumes are measured at 0.5, 1, 2, 3, 4, and 5 hr. Edema can be calculated as the increase in paw volume divided by the starting paw volume. Rats supplemented with D-PUFA are expected to have lower levels of edema as compared to Rats supplemented with H-PUFA.
- arachidonic acid AA
- AA arachidonic acid
- D-PUFA see, e.g., species of Formula (1)
- D-PUFAs 0.01, 0.1, 1.0, 10.0, and 100 mg/kg of D-PUFA
- different combinations of D-PUFAs e.g., 1:1 ratio of two types of D-PUFAs
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- D-PUFA see, e.g., species of Formula (1)
- D-PUFAs 0.01, 0.1, 1.0, 10.0, and 100 mg/kg of D-PUFA
- different combinations of D-PUFAs e.g., 1:1 ratio of two types of D-PUFAs
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- H-PUFA 0.01, 0.1, 1.0, 10.0, and 100 mg/kg
- mice are then injected with 100 ⁇ g bovine type II collagen in Freund’s complete adjuvant (FCA) intradermally at the base of the tail and monitored by daily examination for the onset of disease, which is recorded.
- FCA complete adjuvant
- mice Alternatively, forty-five DBA/1 mice 8-10 weeks of age are injected with 100 ⁇ g bovine type II collagen in Freund’s complete adjuvant (FCA) intradermally at the base of the tail and monitored by daily examination for the onset of disease, which is recorded.
- FCA complete adjuvant
- mice are divided randomly into one of three treatment groups: 1) control; 2) D-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg), and 1:1 or different combinations of different species of D-PUFA) treated; or 3) H-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg), and 1:1 or different combinations of H-PUFA corresponding in type to D-PUFA combinations.
- the severity of arthritis in the affected paw is graded according to an established score system as follows: 0 (normal joint), 1 (mild/moderate visible edema and swelling), 2 (severe edema with distortion of paw and joint) and 3(deformed paw or joint with ankylosis).
- mice All mice are pre-bled prior to the start of the trial, subsequently at onset of arthritis, two weeks post onset, four weeks post onset and at the completion of the trial. Sera obtained from each group is stored at -80° C. until needed. ELISA assays are performed to determine total anti-collagen antibody levels in mouse CIA. D-PUFA treated animals are expected to have reduced signs of arthritis as compared to H-PUFA treated animals and control animals.
- ARDS Acute respiratory distress syndrome
- ARDS is an aggravating condition; ARDS is associated with aging is a contributor to mortality in as many as 40% of deaths. ARDS is often caused by bacterial or viral pneumonia.
- ARDS is usually modeled as acute lung injury (ALI) by instillation of live bacteria (S. pneumoniae or P. aeruginosa) or non-specific damaging factors like ozone.
- Bacterial ALI can be modeled by a sterile single dose challenge with E. coli lipopolysaccharide (LPS).
- LPS E. coli lipopolysaccharide
- FIG. 7 A shows various PUFAs that are used.
- LA linoleic acid
- D2-LA 11,11-D2-linoleic acid
- AA arachidonic acid
- D2-AA 13,13-D2-arachidonic acid (a product of in vivo enzymatic elongation/extension of D2-LA);
- D6-AA 7,7,10,10,13,13-D6-arachidonic acid.
- FIG. 7 B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen, the key rate-limiting step of PUFA oxidation (both enzymatic and LPO), is inhibited by deuteration.
- FIG. 7 B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen, the key rate-limiting step of PUFA oxidation (both enzymatic and LPO), is inhibited by deuteration.
- FIG. 7 B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen, the key rate-limiting step of PUFA
- FIG. 7 C shows multiple products of non-enzymatic LPO include reactive carbonyls like HHE and HNE, which can covalently cross-link biomolecules.
- FIG. 7 D shows numerous products of enzymatic AA oxidation are mostly pro-inflammatory and pro-thrombotic.
- This approach uses the deuteration of the three oxidation prone sites within AA molecule, to substantially slow down the rate limiting step of oxidation (both enzymatic and non-enzymatic) via the isotope effect (IE).
- IE isotope effect
- H-AA dietary arachidonic acid
- D-AA hexadeuterated form
- Bis-allylic D-PUFAs were produced by total synthesis and by catalytic deuteration.
- mice Male and Female BALB/c and C57BL/6 mice were provided with standard environmental conditions i.e., 22 ⁇ 1° C., 55 ⁇ 5% humidity and 12 h light/dark cycle with free food and water access.
- the body weight and food intake were measured once a week.
- mice in each group (10 females and 10 males) (i) underwent the procedure of bronchoalveolar lavage (BAL) to accomplish cytological smears, (ii) were subjected to tissue harvesting and collection of colon contents (after humane euthanasia with lethal dose of sodium thiopental, 100 mg/kg intravenously).
- BAL bronchoalveolar lavage
- the other half of the group was administered 1 mg/kg of intranasal (IN) LPS from Escherichia coli O111:B4 (Sigma Aldrich) 24 hours prior to BAL and subsequent euthanasia.
- I intranasal
- 40 D-AA fed animals (20 males, 20 females) were switched to the H-AA diet for washout experiments.
- lungs were lavaged three times using three aliquots of 1 ml 0.15 M NaCl under deep anesthesia (sodium thiopental). Each lavage consisted of slow infusion and gentle aspiration of saline via tracheal cannula. Three recovered lavages were combined. The samples were centrifuged for 7 minutes at 400 g and 4° C. in a microcentrifuge with a F241.5P rotor (Beckman Coulter, USA). The supernatants were collected and stored frozen at -80° C. no longer than one month before further analysis.
- Cell differential counts were performed on smear slides from resuspended cell pellets of BAL, using commercially available May-Grünwald-Giemsa staining kits. All slides were evaluated in a light microscope (Optec BK5000) at X200 magnification. These cell counts such as lymphocytes, neutrophils, plasmacytes and macrophages were obtained from 10 fields of each slide.
- the severity of lung injury was scored according to lung pathological changes, including interalveolar and perivascular hemorrhages, peri- vascular and peribronchial infiltration, perivascular edema, thickness of alveolar wall, alveolar space value, and emphysematous transformations.
- Lung tissue samples were additionally stained with commercially available Martius Scarlet Blue (MSB) stain kit (Avantik, USA) for fibrin visualization. The presence of homogeneous fibrin masses of yellow, pink or red color in the lung blood vessels were interpreted as thrombotic masses.
- MSB Martius Scarlet Blue
- Colon contents of euthanized mice were collected for microbial community analyses, immediately frozen and stored at -20° C. until analyzed. The samples were slowly thawed at +4° C., serial dilutions (10-3) were prepared, plated on specific media and incubated at 37° C. as follows.
- Microaerophylic flora Enterococci - Enterococcal agar, 48 h; lactobacilli - Lactobacagar, 3 days; bifidobacteria - Bifidum-medium, 5 days, at 37° C.; Aerobes: Staphylococci - medium N10 for 48 h, coliforms - Endo medium for 48 h at 37° C., yeast-like fungi - Saburo agar, 48 h. These specific media were purchased from GNC PMIB (Obolensk, Russia). At the end of the specified incubation periods, colony forming units (CFU) were counted.
- CFU colony forming units
- the relative ratio of H-AA to D-AA was determined by gas chromatography (GC) coupled to chemical ionization mass spectrometry. Briefly, freshly harvested samples were homogenized and extracted by the Bligh and Dyer method, placed in tubes, solvent evaporated, blanketed with dry nitrogen, sealed, and shipped to Austin (TX) for further sample preparation and analysis. Dried samples were converted to fatty acid methyl esters (FAME) by a one-step method of hydrolysis and methylation.
- GC gas chromatography
- TX Austin
- Solvent-medicated (SM) chemical ionization was performed with CH 3 CN as reagent using a Shimadzu GCMS-TQ8040 (Columbia, MD) instrument with a BPX70 capillary column (25 m ⁇ 0.22 mm ⁇ 0.25 ⁇ m; Trajan, Pflugerville, TX). D-AA was chromatographically separated from H-AA. Total ion chromatograms were used to integrate peak areas.
- mice (six weeks old, both genders) received PUFAs of interest once per day via oral gavage 50 ⁇ L per mice.
- mice were intranasally administered with 1 mg/kg of LPS and sacrificed 24 hours later for lung histology.
- the results demonstrate a small, but statistically significant decrease of alveolar wall thickness in D2-LA mice when compared to H-LA group. This could be explained by a more pronounced hyperallergic response of lungs to H-LA compared with D2-LA.
- LPS treatment revealed signs of hyperplasia of bronchial epithelium and its hypersecretion, focal perivascular and peribronchial lymphoid infiltrates together with the presence of serous edema. Histologically, this effect was accompanied by inflammatory cells infiltration through alveolar walls.
- D2-LA is partially converted to D2-AA by the action of fatty acid desaturases 1 and 2 (FADS 1 and FADS2) and by fatty acid elongase 5 (ELOVL5)
- FDS 1 and FADS2 fatty acid desaturases 1 and 2
- ELOVL5 fatty acid elongase 5
- FIG. 8 shows the thickness of interalveolar septa ( ⁇ m) of BALB/c mice after 6 weeks of H- or D-forms of linoleic acid (H-LA and D2-LA) followed by single intranasal administration of lipopolysaccharide. * - p ⁇ 0.05, compared H-LA versus D2-LA mice.
- FIGS. 9 A- 9 C shows D-AA as a % of all AA at eight weeks dosing and washout over the subsequent 9 weeks with H-AA feeding.
- FIG. 9 A shows the graphs for visceral organs and skin. Lung incorporated about 45% D-AA.
- FIG. 9 B shows graphs for neural tissue: whole brains and whole eyes. Both incorporated about 50% D-AA. Washout from eyes was more rapid than brain.
- FIG. 9 C shows lung D-AA and conversion to longer chain PUFA adrenic acid (22:4) by elongation and docosapentaenoic acid (DPA, 22:5) by desaturation. All PUFA followed similar washout kinetics.
- Neural PUFA are uniquely unsaturated, with AA and omega-3 docosahexaenoic acid (DHA) together comprising about 40% of all brain fatty acids, while linoleic acid is below 1%. Lungs are similar to other tissues.
- H-AA and D-AA were well tolerated without apparent adverse reactions. Consumption of the diets for 2, 4, 6 or 8 weeks did not lead to significant changes in the level of IL-1 ⁇ in BAL fluid or large intestine homogenates of conventionally healthy mice, regardless of gender. Macroscopically, the lungs of all groups were normal at the time of euthanasia. Cellular infiltration in the BAL was not significantly affected by either of AA-rich diets. After 8 weeks of feeding AA-rich diets, the number of lymphocytes increased compared to the control. The number of inflammatory cells in cytological smears of lavage was not significantly different between dietary consumption of H- and D-forms.
- mice interalveolar septa thickness depended on duration and were affected by deuteration.
- the average thickness of mice interalveolar septa after H-AA and D-AA diets given for 2 or 4 weeks did not significantly differ.
- alveolar walls of healthy males and females after 8 weeks of H-AA consumption were significantly (p ⁇ 0.05) thicker compared to those in respective D-AA-cohorts.
- No relevant changes of alveolar spaces were observed for AA or for D6-AA diets.
- Analysis of the composition of the intestinal microflora, as well as the enzyme immunoassay of the interleukin level in lavage and intestinal homogenates, did not reveal any significant differences between mice on the diets regardless of the dietary course duration (data not shown).
- mice fed AA-diets for 6 weeks using LPS treatment Twenty-four hours after exposure to LPS, the lung tissue showed intense perivascular, peribronchial, and septal inflammatory infiltration, with a predominance of lymphocytes and macrophages. Perivascular edema, signs of thrombosis, alveolar wall thickening, irregular distribution of air spaces, and focal areas of alveolar hemorrhage were also observed.
- We preferred intranasal administration to the more extreme intratracheal route that induces IL-1 ⁇ which in turn amplifies inflammation making it difficult to distinguish between the early and late consequences of the LPS challenge.
- FIGS. 10 A- 10 C show histological evaluation of the effect of intranasal administration of lipopolysaccharide on the lungs of H-AA and D-AA treated male mice.
- FIG. 10 A corresponds with normal mice lungs;
- FIG. 10 B correspond with lung of mice that are LPS-treated on H-AA diet;
- FIG. 10 C corresponds with lungs of mice that are LPS-treated on D-AA diet.
- the arrow in the figures point to emphysematous areas.
- FIG. 11 shows graphs of the thickness of interalveolar septa ( ⁇ m) after 6 weeks course of H- or D-AA by single intranasal administration of LPS.
- Norm male and female mice without LPS treatment.
- Gender differences are well known to be important in models like ALI. For example, female mice respond more severely to P. aeruginosa. It is believed that estrogen imparts protective effects on LPS-induced acute lung inflammation and hemorrhagic shock-induced lung injury. Conversely, in infectious models that employed P. aeruginosa, females displayed a more robust lung inflammatory response while displaying higher bacterial loads. This underscores the complexities underlying the sex differences in lung immune responses. In our study, the degree of alveolar lumen area changes in both groups of animals also depended on gender: this indicator was significantly lower in females than in males regardless of the form of AA (H or D). Also, in mice on D-AA the severity of changes in thickness of interalveolar septa were significantly higher in males compared to females, correlating well with human cases.
- ARDS can result from direct (e.g. pneumonia, acid aspiration) or indirect (e.g. pancreatitis, non-pulmonary sepsis) injury to the lungs.
- Murine models of direct ALI include those in which agents are delivered intratracheally or intranasally.
- We induced ALI by intranasal administration of E. coli LPS considered to be a common inductor of lung injury and inflammation.
- Dietary consumption of H-AA prior to LPS exposure, depending on its duration, did not improve and even aggravated LPS-induced lung tissue damage, including alveolar wall thickening. The damaging effect of LPS observed against the background of dietary D-AA was substantially mitigated.
- LPS-induced ALI is a well-established model of ARDS.
- LPS activates NF-KB and then NLRP3 inflammasome, leading to secretion of IL-1 ⁇ and IL-18, which further triggers inflammation by positive feedback.
- various treatments reportedly protect from acute LPS effects in the murine models like ouabain, and various other compounds like xanthohumol and corylin, the mechanisms of these protective effects are complex.
- D-PUFA may have a simpler inflammation-reducing mode of action.
- AA AA derived from LA through the enzymatic elongation and desaturation is then incorporated into essentially every tissue. Accordingly, dosing mammals on D2-LA would lead to 13,13-D2-AA ( FIGS. 7 A- 7 D ) tissue incorporation. Deuteration at C13 might lead to inhibition of COX1/2 as well as 15-LOX, reducing the level of some pro-inflammatory species as well as LPO.
- AA is more efficiently incorporated into tissues when consumed as pre-formed AA rather than as LA, with subsequent metabolic conversion to AA. Nevertheless, within a tissue or pool (e.g., plasma phospholipids), AA levels tend to be controlled within relatively tight limits.
- a tissue or pool e.g., plasma phospholipids
- AA levels tend to be controlled within relatively tight limits.
- One effect of dietary AA is the increase in metabolic turnover of tissue AA.
- LPS activates phospholipase A2 leading to the release of free AA into surrounding tissues and blood, modulating overall inflammation on the organism level including sepsis and survival. Accordingly, metabolism of fatty acids may be important for modulation of the acute LPS-induced lung disorder and other conditions.
- Exogenous oxidized phospholipids induce hyperinflammatory reaction in vitro.
- Omega-3 PUFAs downregulate inflammation by competing with AA for LOX and COX.
- some oxidation products of long chain PUFAs e.g., isoprostanes, and neuroprostanes
- mice infected with P. aeruginosa survival was im-proved by fish oil supplementation.
- AA is the major PUFA involved in inflammation.
- peripheral blood lymphocytes and monocytes have been reported to have an average AA content of 16- 20% of total fatty acids.
- AA cleaved and released by phospholipase A2 (PLA2) acts as a substrate for COX, LOX and cytochrome P450, yielding pro-inflammatory eicosanoid mediators and regulators such as prostaglandins, leukotrienes, and thromboxanes.
- PPA2 phospholipase A2
- Patients with acute COPD have increased AA content in sputum. It is suggested that the severity of emphysematous transformations may also correlate in such patients with high AA levels and COX2 converted mediators.
- Pulmonary surfactant covers the large alveolar surface in all mammalian species, stabilizing the alveoli and preventing them from collapse. It is composed of 10% protein and 90% lipids with a predominance of phospholipids (PLs). Within PL, both acyl chains can be either saturated (no double bonds), monounsaturated (one double bond), or polyunsaturated (i.e., more than one double bond, such as in ARA). The structure of surfactant PLs permits them to modulate the host-pathogen interaction as well as to react on environment-induced oxidative stress. Alterations of the pulmonary surfactant system have long been documented in ARDS or, more generally, in any lung disease with pronounced alveolar inflammation.
- n-6 PUFAs i.e., 18:2n-6 and 20:4n-6, the precursors of eicosanoids and leukotrienes
- the ability of enteral feeding to rapidly modulate the PUFAs composition of surfactant may facilitate timely attenuation of eicosanoid-driven inflammatory processes and decrease the risk of developing ARDS
- Excessive AA is pro-inflammatory under certain conditions of viral and bacterial infections that can be modelled by LPS.
- LPS treatment promotes inflammation through various mechanisms including the secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS.
- an acute lung inflammation quickly follows.
- the COVID-19 pandemic is causing severe morbidity and mortality across the globe. Advanced age and other pre-existing conditions result in elevated mortality among COVID-19 patients.
- Many viruses have high affinity towards receptors found in the lungs.
- COVID-19, SARS, MERS and influenza trigger an immune response, attracting immune cells to the region to attack the virus, resulting in localized inflammation.
- cytokine storms ensue, involving excessive uncontrolled production of pro-inflammatory cytokines/chemokines including IL-6, TNF- ⁇ , IFN- ⁇ , IL-2, and IL-7, resulting in hyperinflammation that can be fatal.
- the immune system of younger people is more reliant on innate mechanisms, so it usually produces lower levels of inflammation-driving cytokines.
- COVID patients demonstrate an increased incidence of thrombotic complications (almost half of the patients admitted to the ICU), even with thromboprophylaxis, further contributing to the high mortality rate from COVID due to pulmonary embolism, strokes, and heart attacks. Indeed, AA as well as its oxidation products are elevated in COVID patients.
- Gut microbiota is known to be important for lung infection severity. However, we did not observe any significant differences here - this fact points to the importance of molecular mechanisms intrinsic to the mammalian cells and tissues.
- D-AA may represent a milder approach to treatment of inflammatory lung pathologies.
- D-AA is less prone to either enzymatic or non-enzymatic oxidation and so is more potent in regulatory interactions that do not require chemical conversions.
- AA reduces the LPS-triggered inflammation in macrophages and septic death in mice through binding to MD2.
- D-AA may also be beneficial due to its improved metabolism.
- D-AA may be a viable therapeutic for inflammatory conditions involving enzymatic and non-enzymatic oxidation.
Abstract
Disclosed herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition. The compositions of deuterated arachidonic acid or ester thereof comprise, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.
Description
- This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application No. 63/292,388 filed Dec. 21, 2021, and U.S. Provisional Application No. 63/293,208 filed Dec. 23, 2021, which are incorporated herein by reference in their entirety.
- Arachidonic acid is an n-6 essential polyunsaturated fatty acid (PUFA) present in the human diet. It is an essential PUFA and a building block for phospholipids found in cellular membranes including neuronal cell membranes and neuronal organelles such as the mitochondria and the endoplasmic reticulum, where it is the dominant PUFA. The structure of arachidonic acid includes four double bonds in a 1,4-polyene configuration resulting in three bis-allylic positions and two mono-allylic positions that flank both ends of this configuration. The following structure provides an example of mono-allylic and bis-allylic positions in a 1,4-diene system.
- Arachidonic acid is readily oxidized at the bis-allylic sites either as a substrate of several enzymes (COX1, COX2, various LOX enzymes, and cytochromes P450, etc.) yielding multiple pro-inflammatory and pro-thrombotic eicosanoid mediators such as prostaglandins, leukotrienes and thromboxanes, or by reactive oxygen species (ROS) leading to further pro-inflammatory metabolites. In either case, such oxidation leads to inflammation in all tissues affected, including the lungs.
- The pro-inflammatory and pro-thrombotic eicosanoid mediators then initiate further inflammatory cascades. Arachidonic acid’s role in enzymatic generation of pro-inflammatory mediators is an important property of this PUFA. Indeed, replacing a portion of arachidonic acid in cell membranes by consuming fish rich in long chain n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, has been reported to decrease inflammation merely by a mass balance approach. See, e.g., Calder, Biochem. Soc. Trans., 33(part 2):423-427 (2005).
- In addition, it is well established that the etiology of many diseases involves an increase in the level of ROS which, in turn, initiates non-enzymatic chain reaction of arachidonic acid peroxidation in lipid membranes (LPO). This chain reaction leads to multiple toxic products including other pro-inflammatory mediators. While regulatory enzymes that neutralize oxidized products arising from LPO are present in cells, the increase in the amount of ROS generated by the disease overwhelms these enzymes and leads to an accumulation of pro-inflammatory mediators.
- Both enzymatic and non-enzymatic oxidative transformations happen at any of the three bis-allylic sites within arachidonic acid as the carbon-hydrogen bond strength at these sites is the weakest within the molecule. The key rate limiting step for both types of transformation, termed hydrogen abstraction (a C-H bond cleavage), defines the rate of the whole process. That is to say that disease progression and, as a corollary, increases in inflammation is directly related to the rate of oxidation of the arachidonic acid (enzymatic oxidation) and oxidation of PUFAs in general (LPO oxidation).
- Oxidative processes involving arachidonic acid are a key component in the generation of inflammatory processes in vivo. As is well established, chronic inflammation has deleterious impacts on patients. For example, the presence of chronic vascular inflammation has been implicated as a causative factor in coronary artery disease. Likewise, chronic arthritic conditions are associated with varying levels of pain, and disfigurement (especially in fingers) is also due to uncontrolled and chronic inflammatory processes.
- Chronic pain associated with arthritis can be controlled in many cases with monoclonal antibodies such as TNF-alpha blockers. However, these antibodies carry substantial risks such as invasive fungal, bacterial, and viral infections, as well as lymphoma and other malignancies, some fatal, especially in children and adolescent patients. In many patients, such risks are unacceptable.
- Accordingly, methods and compositions that control inflammation without the use of monoclonal antibodies would be of particular importance.
- Provided herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition, D6-AA has a long half-life such that when a therapeutic concentration is reached, the patient will experience long term control of chronic inflammatory process and long term control of the chronic pain.
- In one embodiment, there is provided a method for controlling chronic inflammation in a patient which method comprises administering an effective amount of a composition comprising D6-AA to said patient for an effective period of time such that the accumulated D6-AA in the cellular membranes attenuates the inflammatory process, thereby controlling the chronic inflammation in the patient.
- In one embodiment, a method for controlling chronic inflammation in a patient, as described herein, provides relief from chronic pain associated with the chronic inflammation.
- In some embodiments, most or all of the hydrogens at the 7, 10 and 13 positions have been replaced as shown below:
- In other embodiments, the methods described herein comprise a composition designated as D6-AA which composition comprises D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites have been replaced by deuterium atoms. For example, in the case of an average of 85% deuteration of the 3 bis-allylic sites and 20% deuteration of the mono-allylic sites, the total amount of deuterium is (6 × 0.85) + (4 × 0.2) = 5.9 (exclusive of the naturally occurring amount of deuterium) in each of the remaining methylene and methyl groups within the structure.
- In one embodiment, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable excipient and from about 10 mg to about 2,000 mg of a composition of D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, has no more than about 30% of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
- In one embodiment, the chronic inflammation is vascular inflammation.
- In one embodiment, the chronic inflammation is inflammation associated with arthritis. In one embodiment, the arthritis is rheumatoid arthritis. In one embodiment, the arthritis is osteoarthritis. In one embodiment, the chronic inflammation is neuroinflammation.
- In one embodiment, the chronic inflammation is associated with a neurodegenerative disease.
- Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:
-
FIG. 1 Different bis-allylic sites may play a different role in oxidation of arachidonic acid. -
FIG. 2 Bis-allylic site-specific isotopically modified arachidonic acids. The bis-allylic positions are located at the C7, C10, and C13 positions. “D” represents deuterium. -
FIGS. 3-6 Groups of female (f) and male (m) mice received a 6-week course of dietary (H) AA or a 6-week course of deuterated arachidonic acid (D6-ARA, 15 mg/day) followed by single intranasal administration of LPS. Control mice (norm) did not receive the single intranasal administration of LPS. Mice that received dietary AA showed an increase of the alveolar lumen area (FIG. 3 is the median;FIG. 4 is the average) and an increase of the interalveolar septa thickness (FIG. 5 is the median;FIG. 6 is the average), which is likely associated with stronger edema and inflammatory infiltration. Mice that received D6-ARA exhibited alveolar lumen area and thickness consistent with controls. In general, the data ofFIGS. 3-6 indicate a lesser degree of inflammatory lesion of the lungs after course of D-form compared to H-form. Preliminary data (not shown) indicates that D6-ARA had the best protective effect as compared to other deuterated PUFAs. -
FIGS. 7A-D show various molecules and reactions relating to PUFAs.FIG. 7A shows various PUFAs.FIG. 7B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen.FIG. 7C shows multiple products of non-enzymatic lipid peroxidation (LPO).FIG. 7D shows numerous products of enzymatic arachidonic acid oxidation. -
FIG. 8 shows the thickness of interalveolar septa of BALB/c mice treated with PUFAs. -
FIGS. 9A-9C shows deuterated arachidonic acid as a % of all arachidonic acid at eight weeks dosing and washout over the subsequent 9 weeks with H-AA feeding.FIG. 9A shows the graphs for visceral organs and skin.FIG. 9B shows graphs for neural tissue: whole brains and whole eyes.FIG. 9C shows lung arachidonic acid and conversion to longer chain PUFAs. -
FIGS. 10A-C show histological evaluation of the effect of intranasal administration of lipopolysaccharide on the lungs of treated male mice. -
FIG. 11 shows graphs of the thickness of interalveolar septa. - In the following detailed description, reference is made to the accompanying figures, which form a part hereof. In the figures, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, figures, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.
- Although certain embodiments and examples are disclosed below, inventive subject matter extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses, and to modifications and equivalents thereof. Thus, the scope of the claims appended hereto is not limited by any of the particular embodiments described below. For example, in any method or process disclosed herein, the acts or operations of the method or process may be performed in any suitable sequence and are not necessarily limited to any particular disclosed sequence. Various operations may be described as multiple discrete operations in turn, in a manner that may be helpful in understanding certain embodiments, however, the order of description should not be construed to imply that these operations are order dependent. Additionally, the structures, systems, and/or devices described herein may be embodied as integrated components or as separate components.
- For purposes of comparing various embodiments, certain aspects and advantages of these embodiments are described. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, for example, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.
- Disclosed are methods for controlling inflammation in a patient. In one embodiment, the inflammation is due to intracellular accumulation of pro-inflammatory oxidized PUFA products.
- Prior to discussing this invention in more detail, the following terms will first be defined. Terms that are not defined are given their definition in context or are given their medically acceptable definition.
- The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
- As used herein, the term “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
- As used herein, the term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations which may vary by ( + ) or ( - ) 15%, 10%, 5%, 1%, or any subrange or subvalue there between. Preferably, the term “about” when used with regard to a dose amount means that the dose may vary by +/- 10%.
- As used herein, the term “comprising” or “comprises” is intended to mean that the compositions and methods include the recited elements, but not excluding others.
- As used herein, the term “consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
- As used herein, the term “consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
- The term “D6-arachidonic acid” or “D6- AA” means a composition that comprises, on average, at least about 4.8 to about 7.2 deuterium atoms in the arachidonic acid (excluding the ester portion thereof if employed). In one embodiment, this includes 7,7,10,10,13,13-D6-arachidonic acid or esters thereof. In another embodiment, this includes compositions of deuterated arachidonic acid or ester thereof that comprises, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.
- In some embodiments, the amount of deuterium replacing hydrogen at the bis-allylic sites (7, 10 and 13) and at the mono-allylic sites (4 and 16) of arachidonic acid can be any one of the following (all percentages are on an average basis): at least about 85% deuterium at bis-allylic sites / no more than about 30% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 25% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 20% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 10% at mono-allylic sites; at least about 85% deuterium at bis-allylic sites / no more than about 5% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 30% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 25% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 20% at mono-allylic sites; at least about 90% deuterium at bis-allylic sites / no more than about 10% at mono-allylic sites; and at least about 90% deuterium at bis-allylic sites / no more than about 5% at mono-allylic sites.
- As used herein and unless the context dictates otherwise, the term “an ester thereof” refers to a C1-C6 alkyl esters, glycerol esters (including monoglycerides, diglycerides and triglycerides), sucrose esters, phosphate esters, and the like. The particular ester group employed is not critical provided that the ester is pharmaceutically acceptable (non-toxic and biocompatible). In one embodiment, the ester is a C1-C6 alkyl ester which is preferably an ethyl ester.
- As used herein, the term “phospholipid” refers to any and all phospholipids that are components of the cell membrane or other lipid membrane(s) within a cell. Included within this term are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin. In the motor neurons, the cell membrane is enriched in phospholipids comprising arachidonic acid.
- The term “bis-allylic site” refers to the methylene group (CH2) separating two double bonds as depicted above.
- The term “mono-allylic site” refers to the methylene group having an adjacent neighboring double bond on one side and a further methylene group on the opposite side as depicted above.
- The term “cellular component” refers to any relevant structure found in human cells, including organelles having a lipid or phospholipid wall. Examples of such cellular components include, by way of example only, the mitochondria, the endoplasmic reticulum, golgi apparatus, nuclear membrane, and the like. Cellular components also include the cell membrane (plasma membrane).
- The term “regulatory enzymes” as it relates to the neutralization of oxidized arachidonic acid products refer to those enzymes that are responsible to remove, alter, or destroy one or more of the oxidized arachidonic acid products from the cells to prevent the accumulation of these oxidized products within the cell. Examples of regulatory enzymes include glutathione peroxidase (GPx) enzymes, particularly GPx4. When these enzymes are impaired, such impairment results in the accumulation of lipid peroxides leading to loss of functionality, which is often death followed by cell death. Gaschler, et al., Biochem. Biophys. Res. Commun., 482(3):419-425 (2017).
- The term “oxidized PUFA products” refer to any oxidized form of a polyunsaturated fatty acid as well as any and all metabolites formed from the oxidized PUFA including reactive aldehydes, ketones, alcohols, carboxyl derivatives which are either pro-inflammatory metabolites or are precursors of pro-inflammatory metabolites.
- The term “neutralization of oxidized products” refers to enzymatic processes that remove, alter, or destroy toxic oxidized PUFA products from the cells to prevent the accumulation of these oxidized products within the cell. In healthy individuals, the neutralization of the oxidized PUFA products prevents accumulation of these products thereby assuring that dysfunctionality of cells especially neurodegenerative cells is controlled.
- As used herein, the term “pathology of a disease” refers to the cause, development, structural/functional changes, and natural history associated with that disease. Included in the pathology of the disease is the reduction in cellular functionality. The term “natural history” means the progression of the disease in the absence of treatment per the methods described herein, for example, prior to the commencement of treatment as described herein.
- As used herein, the term “chronic inflammation” refers to known conditions where inflammation plays a key role in the development and progression of chronic diseases including, but not limited to, autoimmune diseases, neurodegenerative diseases, metabolic disorders such as atherosclerosis and obesity, fibrosis, and cancer to name a few. Such diseases also include asthma, arthritis including rheumatoid arthritis, juvenile chronic arthritis, osteoarthritis, myossitis, Crohn’s disease, gastritis, colitis, ulcerative colitis, inflammatory bowel disease, proctitis, pelvic inflammatory disease, systemic lupus, erythematosus, rhinitis, conjunctivitis, scleritis, chronic inflammatory polyneuropathy, Lyme’s disease, psoriasis, dermatitis, and eczema, neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis to name a few. Such diseases are deemed chronic as the condition involved is either lifelong (after diagnosis) such as autoimmune diseases or which take substantially long periods of time to treat and resolve such as obesity.
- As used herein, the term “control” or “controlling” as it relates to chronic inflammation means that the extent of inflammation arising from a chronic disease has been decreased or attenuated over time such that the degree of discomfort or pain arising in the patient is reduced. While the level of discomfort felt by a patient is personal and distinct from other patients suffering through the same disease, the decrease in inflammation can be measured by the extent of swelling, a decrease in C Reactive Protein (CRP), and other standards well known in the art. Preferably, a decrease of at least 15% and preferably at least 35% in CRP concentrations between start of therapy and 45 days or 90 days post start of therapy evidence control of the inflammation.
- The term “therapeutic concentration” means an in vivo concentration of a deuterated arachidonic acid that controls chronic inflammation. In one embodiment, a concentration of D6-AA in red blood cells of at least about 1% and preferably at least from about 1.5% to about 6% based on the total amount of arachidonic acid found therein (including deuterated arachidonic acid) will be therapeutic.
- As used herein, the term “patient” refers to a human patient or a cohort of human patients suffering from a neurodegenerative disease treatable by administration of a prodrug of deuterated arachidonic acid.
- As used herein, the term “pharmaceutically acceptable salts” of compounds disclosed herein are within the scope of the methods described herein and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable). When the compound has a basic group, such as, for example, an amino group, pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid). When the compound has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na+, Li+, K+, Ca2+, Mg2+, Zn2+), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g., arginine, lysine, and ornithine). Such salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
- Inflammation-related disorders represent a heterogeneous group of diseases that have a common underlying inflammatory pathology. For example, inflammation-related disorders include, but are not limited to, asthma, rheumatoid arthritis, juvenile chronic arthritis, osteoarthritis, myositis, Crohn’s disease, gastritis, colitis, ulcerative colitis, inflammatory bowel disease, proctitis, pelvic inflammatory disease, systemic lupus erythematosus, rhinitis, conjunctivitis, scleritis, chronic inflammatory polyneuropathy, Lyme disease, psoriasis, dermatitis, eczema, autoimmune disorders, neurodegenerative disorders, and atherosclerosis.
- Inflammation-related disorders often involve increased generation of ROS (reactive oxygen species) and lipid processing abnormalities (Winyard PG et al. Free radicals and inflammation. Burkhauser, Basel, 2000; Filippo et al., Journal of Alzheimer’s Disease (2010); 20, S369-S379). The combination of ROS and lipid processing abnormalities leads to increased PUFA peroxidation that generates toxic reactive carbonyl compounds which inflict further damage at numerous other sites within the cell (Negre-Salvayre A et al., Br J Pharmacol 2008;153:6-20). Consequently, the detection of oxidatively damaged biomolecules and the presence of ROS in inflammatory states both implicate elevated oxidative stress levels.
- Lipid peroxidation is important in atherosclerosis and in worsening of initial tissue injury caused by ischemic or traumatic brain damage. Atherosclerosis is a lipid storage disorder associated with inflammatory response (Ross R, New Engl J Med. 1999;340:115-127).
- Oxidation of PUFA-rich low-density lipoprotein (LDL) was suggested to be a major risk factor for atherosclerosis and for hypertension associated with atherosclerosis. Angiotensin II (Ang-II) is involved in this process, enhancing macrophage lipid peroxidation both in vivo and in vitro (Keidar S. Life Sci. 1998;63: 1-11). Despite the importance of oxidative stress in the etiology of atherosclerosis, the success of antioxidant therapies aiming to reduce lipid peroxidation has so far been limited (Stocker R et al., Physiol Rev 2004;84:1381-1478).
- Rheumatoid arthritis may be associated with inflammation and PUFA peroxidation through a reperfusion injury mechanism. The synovial cavity normally has a negative pressure. When the joint is exercised, vascular patency is maintained, allowing for nutrition of the avascular cartilage. In rheumatoid synovitis, the cavity pressure is raised and upon movement this pressure exceeds the capillary perfusion pressure, causing collapse of the blood vessels. This leads to the production of multiple episodes of′hypoxic-reperfusion injury’ generating ROS which oxidize several targets, including, but not limited to: IgG, inducing rheumatoid factor production; Hyaluronan, leading to hyaluronan fragmentation products which may alter immune function; PUFAs, generating reactive carbonyls which alter T cell/macrophage interactions; and lipoproteins, leading to the production of monocyte chemotactic peptides. Progressive hypoxia alters immune function, predominantly by calcium mediated pathways. (Mapp PI et al., Br Med Bull 1995;51:419-436). Various PUFA peroxidation products including, but not limited to, conjugated dienes, isoprostanes and reactive aldehydes such as HNE are detectable in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis patients (Selley ML Annals Rheum Disease 1992;51:481-484).
- Oxidative damage is implicated in a wide variety of diseases such as mitochondrial diseases, neurodegenerative diseases, neurodegenerative muscle diseases, retinal diseases, energy processing disorders, kidney diseases, hepatic diseases, lipidemias, cardiac diseases, inflammation, and genetic disorders.
- Oxidative stress at sites with chronic inflammation can also cause genetic changes. Reactive carbonyl products of PUFA peroxidation can react with DNA bases and change their complementarity pattern (Esterbauer H et al., Free Rad Biol Med 1991;11:81-128). The development of mutations in the p53 tumor suppressor gene and other key regulatory genes can convert inflammation into chronic disease in rheumatoid arthritis and other inflammatory disorders (Tak PP et al.,
Immunology Today 2000;21:78-82). - While the number of diseases associated with oxidative stress are numerous and diverse, it is well established that oxidative stress is caused by disturbances to the normal redox state within cells. An imbalance between routine production and detoxification of reactive oxygen species (ROS) such as peroxides and free radicals can result in oxidative damage to cellular structures and machinery. Under normal conditions, a potentially important source of ROS in aerobic organisms is the leakage of activated oxygen from mitochondria during normal oxidative respiration. Additionally, it is known that macrophages and enzymatic reactions also contribute to the generation of ROS within cells. Because cells and their internal organelles are lipid membrane-bound, ROS can readily contact membrane constituents and cause lipid oxidation. Ultimately, such oxidative damage can be relayed to other biomolecules within the cell, such as DNA and proteins, through direct and indirect contact with activated oxygen, oxidized membrane constituents, or other oxidized cellular components. Thus, one can readily envision how oxidative damage may propagate throughout a cell give the mobility of internal constituents and the interconnectedness of cellular pathways.
- PUFAs endow mitochondrial membranes with appropriate fluidity necessary for optimal oxidative phosphorylation performance. PUFAs also play an important role in initiation and propagation of the oxidative stress. PUFAs react with ROS through a chain reaction that amplifies an original event (Sun M, Salomon RG, J. Am. Chem. Soc. 2004; 126:5699-5708). However, nonenzymatic formation of high levels of lipid hydroperoxides is known to result in several detrimental changes. Indeed, Coenzyme Q10 has been linked to increased PUFA toxicity via PUFA peroxidation and the toxicity of the resulting products (Do TQ et al., PNAS USA 1996; 93:7534-7539). Such oxidized products negatively affect the fluidity and permeability of their membranes; they lead to oxidation of membrane proteins; and they can be converted into a large number of highly reactive carbonyl compounds. The latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al., Brit. J. Pharmacol. 2008; 153 :6-20). But the most prominent products of PUFA oxidation are alpha, beta-unsaturated aldehydes such as 4-hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), 4-hydroxyhex-2-enal (4-HHE; formed from n-3 PUFAs like ALA or DHA), and corresponding ketoaldehydes (Esterfbauer H, et al., Free Rad. Biol. Med. 1991; 11:81-128; Long EK, Picklo MJ. Free Rad. Biol. Med. 2010; 49:1-8). These reactive carbonyls cross-link (bio)molecules through Michael addition or Schiff base formation pathways and have been implicated in a large number of pathological processes (such as those introduced above), age-related and oxidative stress-related conditions, and aging. Importantly, in some cases, PUFAs appear to oxidize at specific sites because methylene groups of 1,4-diene systems (the bis-allylic position) are substantially less stable to ROS, and to enzymes such as cyclooxygenases, cytochromes and lipoxygenases, than allylic methylenes.
- Eicosanoids are important cell signaling molecules involved in an array of physiological and pathological processes, including various immune responses such as promoting inflammation, inhibiting inflammation, allergy, and fever. There are multiple oxidative and immune response related pathways in the biosynthesis of eicosanoids from arachidonic acid.
- In one pathway, the enzyme 5-lipoxygenase (5-LO or ALOX5) converts arachidonic acid (ARA) into 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene A4 (LTA4), which is then converted into different leukotrienes (LTC4, LTD4, and LTE4) by downstream enzymes. LTC4, LTD4, and LTE4 are potent bronchoconstrictors and stimulators of mucus secretion in lung tissue and are known to promote hypersensitivity reactions in respiratory conditions such as asthma.
- In another pathway leading to oxidative and inflammatory responses, 15-lipoxygenase (15-lipoxygenase 1, 15-LOX, 15-LOX1, or ALOX15) and 12-lipoxygenase (12-LOX or ALOX12) metabolize arachidonic acid to form 15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HPETE) and 12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HPETE). Both 15(S)-HPETE and 12(S)-HPETE are further reduced by cellular glutathione peroxidase to their corresponding hydroxy analogs, 15-hydroxyicosatetraenoic acid (15(S)-HETE) and 12-hydroxyeicosatetraenoic acid (12(S)-HETE), respectively. 15(S)-HPETE and 15(S)-HETE are further metabolized to various bioactive products such as lipoxins, hepoxillins, eoxins, 8(S),15(S)-diHETE, 5(S), 15(S)-diHETE and 15-oxo-eicosatetraenoic acid (15-oxo-ETE). The 12/15-lipoxygenase metabolities have been shown to have both pro- and anti-inflammatory properties.
- In yet another pathway, COX1 and COX2 (also known as prostaglandin-endoperoxide synthase-1 (PTGS1) and PTGS2, respectively) initiates metabolization of arachidonic acid to a subclass of eicosanoids that includes prostaglandins (such as prostacyclins), and thromboxanes. Prostaglandins are mediators of inflammatory and anaphylactic reactions and thromboxanes are mediators of vasoconstriction and platelet aggregation, playing a major role in blood clotting.
- In another pathway, cytochrome P450 enzymes metabolize arachidonic acid to EETs (epoxyeicosatrienoic acids). EETs can promote the active termination of inflammation through mediating a broad array of anti-inflammatory and pro-resolving mechanisms.
- Prior studies have examined the relative enzymatic activity of cyclooxygenases and lipoxygenases upon isotopologues of arachidonic acid deuterated at bis-allylic positions, but these were mechanistic studies that did not use deuterated arachidonic acid in physiological or therapeutic amounts. One study tested the enzymatic activity of purified COX and LOX on different isotopologues of arachidonic acid, but the study did not test activity in cells. (Chistyakov, D., et al., Deuterated Arachidonic Acids Library for Regulation of Inflammation and Controlled Synthesis of Eicosanoids: An In Vitro Study, Molecules, 2018, 23:3331; which is hereby incorporated by reference in its entirety.) In another study, a macrophage cell-line was incubated with D-AA or normal AA, and cell-culture supernatants were analyzed for the amount of eicosanoids produced and secreted. However, this study used non-physiological conditions where arachidonic acid at a molar concentration of 25 micromolar was incubated with the cells for 24 hours, which resulted in incorporation of up to 90% of the arachidonic acid in cell membranes — a percentage unattainable by several-fold under physiological conditions. (Navratil, A. et al., Lipidomics Reveals Dramatic Kinetic Isotope Effects during the Enzymatic Oxygenation of Polyunsaturated Fatty Acids Ex Vivo). Thus, neither study has shown whether compositions comprising bis-allylic isotopically modified essential PUFAs, including arachidonic acid, can inhibit inflammation in vivo, which is important given the multiple metabolic pathways involving arachidonic acid and the potential pro- and anti-inflammatory effects resulting therefrom. Further, the purified enzymatic study (Chistyakov et al.) and the cell assay (Navratil et al.) both used very high concentrations of the designated AA species in the absence of other PUFAs and did not examine biologically relevant complex mixtures of fatty acids present at low concentrations, and enzymatic products derived therefrom, whether in in vitro or in vivo model systems.
- Apart from the pro inflammatory enzymatic products of AA oxidation, the second major element of inflammation is the non-enzymatic chain reaction of PUFA damage, known as lipid peroxidation (LPO), which may be initiated by enzymes or by small molecule ROS. This pro-inflammatory non-enzymatic component is impervious to antioxidant approaches due to the structural aspects of the lipid bilayers making up membranes Inflammation associated LPO can be initiated through various mechanisms. (Zhang et al., Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation, J Blot Chem 2002 doi: 10.1074/jbc.M209124200).
- Arachidonic acid is readily oxidized at the bis-allylic sites either as a substrate of several enzymes (COX1, COX2, various LOX enzymes, and cytochromes P450, etc.) yielding multiple pro-inflammatory and pro-thrombotic eicosanoid mediators such as prostaglandins, leukotrienes and thromboxanes, which then initiate further inflammatory cascades. Additionally, oxidation can occur via reaction with reactive oxygen species (ROS) leading to further pro-inflammatory metabolites. In either case, such oxidation leads to inflammation in all tissues affected, including the lungs.
- Inflammation increases the level of reactive oxygen species (ROS) which in turn initiate non-enzymatic chain reaction of AA peroxidation in lipid membranes (LPO), leading to multiple toxic products. In addition, it is well established that the etiology of many diseases involves an increase in the level of ROS which, in turn, initiates non-enzymatic chain reaction of arachidonic acid peroxidation in lipid membranes (LPO). This chain reaction leads to multiple toxic products including other pro-inflammatory mediators. While regulatory enzymes that neutralize oxidized products arising from LPO are present in cells, the increase in the amount of ROS generated by the disease overwhelms these enzymes and leads to an accumulation of pro-inflammatory mediators.
- Both enzymatic and non-enzymatic AA oxidative transformations happen at any of the three bis-allylic sites within the AA molecule as the carbon-hydrogen bond strength at these sites is the weakest within the molecule. The key rate limiting step for both types of transformation, termed hydrogen abstraction (a C-H bond cleavage), defines the rate of the whole process. That is to say that disease progression and, as a corollary, increases in inflammation is directly related to the rate of oxidation of the arachidonic acid (enzymatic oxidation) and oxidation of PUFAs in general (LPO oxidation). Thus, the present disclosure provides therapeutic methods based on the concept that AA oxidation plays a pivotal role in multiple aspects of inflammatory disorders, including cytokine storm and thrombotic complications.
- COX and LOX inhibitors can be employed to down-regulate this process, with various efficacy. In contrast, the methods of the present disclosure rely on deuteration of the three oxidation prone sites within PUFA molecules, to substantially slow down the rate limiting step of oxidation (both enzymatic and non-enzymatic) via the isotope effect (IE). Made in high yield via a catalytic process, such D-PUFAs were tested in a lipopolysaccharide (LPS)-inflicted lung inflammation model in mice, a well-known lung inflammation model. (See Example 1.)
- Intranasal administration of lipopolysaccharide (LPS), a bacterial endotoxin, has been shown to initiate a pro-inflammatory response in the lungs of mice. For example, the mouse LPS model has been used as a model for human acute lung injury (ALI), as the mouse lung parenchyma is damaged by the generation and release of proteases and reactive oxygen and nitrogen species produced by activated lung macrophages and transmigrated neutrophils in the interstitial and alveolar compartments. The end results are microvascular injury and diffuse alveolar damage with intrapulmonary hemorrhage, edema, and fibrin deposition (Johnson and Ward, J. Clin. Invest., (1974), 54:349-357; Flierl et al., Med. Hypothesis Res., (2006), 3:727¬738), which are also features in patients with ALI and the acute respiratory distress syndrome (ARDS) (Kabir et al., Shock, (2002), 17:300-303; Ward, Am. J. Pathol., (1996), 149:1081-1086). This LPS model recapitulates aspects of the inflammatory cascades that are associated with pulmonary inflammation associated with lung disease in humans, and so is useful as a screen for compounds that may disrupt these cascades and attenuate or abort the disease process. As discussed herein, in some embodiments, the D-PUFAs of the disclosure are administered to break the inflammatory cascade of specific cytokines and chemokines known to induce and amplify lung inflammation. Thus, for example, one can experimentally assess the efficacy of the D- PUFAs by examining whether the levels of inflammation associated markers are reduced. Two such markers, monocyte chemoattractant protein (MCP-1), and tumor necrosis factor alpha (TNF-a), are found to be associated with early and chronic infection and inflammation in humans and are mirrored in rodent models of airway inflammation including the mouse LPS pulmonary inflammation model.
- The pro-inflammatory and pro-thrombotic eicosanoid mediators then initiate further inflammatory cascades. Arachidonic acid’s role in enzymatic generation of pro-inflammatory mediators is an important property of this PUFA. Indeed, replacing a portion of arachidonic acid in cell membranes by consuming fish rich in long chain n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, has been reported to decrease inflammation merely by a mass balance approach. See, e.g., Calder, Biochem. Soc. Trans., 33(part 2):423-427 (2005).
- Oxidative processes involving arachidonic acid are a key component in the generation of inflammatory processes in vivo. As is well established, chronic inflammation has deleterious impacts on patients. For example, the presence of chronic vascular inflammation has been implicated as a causative factor in coronary artery disease. Likewise, chronic arthritic conditions are associated with varying levels of pain, and disfigurement (especially in fingers) is also due to uncontrolled and chronic inflammatory processes.
- The resulting pathology of chronic inflammatory diseases differs from the underlying etiology of the disease. That is to say that whatever divergent conditions trigger each of these diseases (the etiology), once triggered the pathology of these diseases involves the accumulation of pro-inflammatory oxidized PUFA products that are pro-inflammatory metabolites or are precursors to pro-inflammatory metabolites. As the amounts of oxidized products increases, the extent of the inflammatory response increases as such oxidized PUFA products activate the biological cascade leading to inflammation.
- As per the above, the increasing concentration of oxidized PUFA products in cells correlates with the progression of the chronic disease that impacts these cells. The methods described herein provide for in vivo delivery of deuterated arachidonic acid to these cells, thereby limiting the amount of oxidized PUFA products generated as both LPO and enzymatic oxidation of arachidonic acid are reduced. Taken together, these two mechanisms either alone or in combination create oxidative stress on the cell. Reduction in the oxidative stress has a positive impact on treating the disease as well as the underlying inflammation. Thus, unlike monoclonal antibodies and other steroidal or non-steroidal anti-inflammatory products, the composition of this invention attenuates both the inflammatory component of the disease as well as addresses the underlying disease itself. This is because the ability of the disease to induce LPO and/or enzymatic oxidation of arachidonic acid is reduced by reinforcing the cell membranes of at-risk cells with D6-AA. In turn, this protects against cell lysis - a mechanism well known to release of pro-inflammatory cytokines and other intracellular components into the extracellular medium.
- The origin of the oxidative stress varies due to differences in the underlying etiology but typically involve one or more different reactive oxygen species. Regardless of the differences in etiology, the production of oxidized PUFA products evidences an imbalance between routine production and detoxification (neutralization) of these oxidized products. The lipid membrane of the cell as well as that of the endoplasmic reticulum and mitochondria of neurons comprise arachidonic acid (a 20-carbon chain polyunsaturated fatty acid (“PUFA”) having 4 sites of cis-unsaturation). Separating each of these 4 sites are 3 bis-allylic methylene groups. These groups are particularly susceptible to oxidative damage as compared to allylic methylene and methylene groups. Apart from leading to further membrane damage, oxidation of arachidonic acid reduces the local concentration of arachidonic acid and must be replaced. Thus, it is a double hit: a positive bioactive membrane component is converted to a toxic membrane component.
- Given that certain cells have a high concentration of arachidonic acid in their lipid membranes, replacement of damaged or lost arachidonic acid in these membranes with deuterated arachidonic acid reinforces these structures in the cell and protects against formation of oxidized lipid products. For example, once a bis-allylic methylene group in one arachidonic acid is oxidized by a ROS, a cascade of further oxidation of other arachidonic acid groups in the lipid membrane occurs. This is because a single ROS generates oxidation of a first arachidonic acid component through a free radical mechanism which, in turn, can oxidize a neighboring arachidonic acid through the same free radical mechanism which yet again can oxidize another neighboring arachidonic acid in a process referred to as lipid chain auto-oxidation. The resulting damage includes a significant number of oxidized arachidonic acid products in the cell membrane and in the membrane of organelles. However, if an oxidized arachidonic acid is adjacent to the deuterated arachidonic acid, then that deuterated arachidonic acid acts as a chain-reaction terminator due to the much higher stability of the carbon-deuterium bond against oxidation as compared to the carbon-hydrogen bond.
- Oxidized arachidonic acid and other oxidized PUFA products negatively affect the fluidity and permeability of cell membranes in the patient’s neurons. In addition, they can lead to oxidation of membrane proteins as well as be converted into a large number of highly reactive carbonyl compounds. The latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al., Brit. J. Pharmacol. 2008; 153:6-20). The most prominent products of arachidonic acid oxidation are alpha, beta-unsaturated aldehydes such as 4-hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), and corresponding ketoaldehydes (Esterfbauer H, et al., Free Rad. Biol. Med. 1991; 11:81-128). As noted above, these reactive carbonyls cross-link (bio)molecules through Michael addition or Schiff base formation pathways, continuing the underlying pathology of the disease. Each of these metabolites derived from oxidized PUFAs are encompassed by the term “oxidized PUFA product(s).”
- Inflammation leads to an increase in inflammatory markers such as C-reactive protein (CRP) and Creatine Kinase (CK) [including CK-BB (brain), CK-MB (heart) and CK-MM (skeletal muscle)]. When a patient is diagnosed with a specific chronic inflammatory disease, the clinician can monitor the patient’s CRP or the CK count to determine the efficacy of the therapy. The treatment described herein provides for a steady increase in the amount of deuterated arachidonic acid in the patient’s cells over time until the concentration reaches an amount that reduces the amount of oxidative stress in the cells which results in inflammation. Replacement of from about 1 to about 5 percent of the arachidonic acid components in a patient’s red blood cells with the D6-AA occurs over about a twenty (20) to forty-five (45) day period during which a gradual decrease in the patient’s CRP or CK can be observed. Typically, around
day 30, the CRP or CK levels in the patient are lower to significantly lower than before the start of therapy evidencing the anti-inflammatory properties of the drug. As more D6-AA or an ester thereof is administered to the patient, its concentration in the cell will reach about 5% to about 20% or more in his/her red blood cells. In all cases, the in vivo concentration of D6-AA is measured by using red blood cells as a proxy for the cells at risk of or undergoing oxidative stress. The stated percent of D6-AA in these cells is measured based on the total weight of arachidonic acid in the red blood cells including D6-AA. - Without being limited to any theory, the progression of a chronic inflammatory disease correlates with the increase in oxidative stress in the cell including the accumulation of oxidized PUFAs. Therapeutic intervention as per the methods described herein limits further increases in oxidative stress and then reduces these levels to control the inflammation associated therewith. Regardless of the theoretical aspects, the examples provided below illustrate the significant reduction of inflammation achieved by D6-AA.
- In one embodiment, the chronic inflammation is vascular inflammation.
- In one embodiment, the chronic inflammation is inflammation associated with arthritis. In one embodiment, the arthritis is rheumatoid arthritis. In one embodiment, the arthritis is osteoarthritis. In one embodiment, the chronic inflammation is neuroinflammation.
- Deuterated arachidonic acid is known in the art. For example, 7,7,10,10,13,13-D6-arachidonic acid is disclosed by Shchepinov, et al., Molecules, 28(12):31 et seq. (2018). Likewise, catalytic deuteration of arachidonic acid using a ruthenium catalyst resulting in about 80% or more deuteration of the bis-allylic sites and about 30% or less deuteration at the mono-allylic sites is disclosed by Shchepinov, et al., U.S. Pat. No. 10,730,821. Both of these references are incorporated herein by reference in their entirety. Still further, other deuterated arachidonic acid compounds are known in the art. Conversion of each of these PUFAs into the corresponding esters are well known in the art.
- In one embodiment, the methods described herein comprise the administration of D6-AA or an ester thereof to a patient suffering from a chronic inflammatory disease. In vivo, the D6-AA slowly accumulates in the cells of the body including those that are subject to chronic inflammation. The clinician can monitor the progress of the therapy by measuring the amount of C-reactive protein (CRP) in the patient as chronic inflammatory diseases generate higher CRP levels and a reduction in that inflammation corresponds to a reduction in the CRP levels. In addition, the clinician can correlate lower CRP levels with increasing concentrations of D6-AA in red blood cells over time. As the concentration of D6-AA in red blood cells increases, CRP levels are expected to fall.
- The methods described herein provide for rapid onset of a therapeutic concentration of deuterated arachidonic acid in vivo. In one embodiment, there is provided a method for reducing inflammation of a chronic inflammatory disease in an adult patient, the method comprising periodically administering D6-AA or an ester thereof to the patient with a dosing regimen that comprises a primer dose and a maintenance dose.
- In an embodiment, the primer dose comprises periodic administration of deuterated arachidonic acid or an ester thereof. In an embodiment, the primer dose comprises at least about 10 milligrams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 10 milligrams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 0.10 grams to about 1 gram. In an embodiment, the primer dose is continued for about 15 to about 50 days or from about 30 days to about 45 days, e.g., to rapidly achieve a therapeutic concentration of deuterated arachidonic acid in vivo, thereby reducing the rate of disease progression.
- In an embodiment, after completion of the primer dose, the maintenance dose is periodically administered. In an embodiment, no more than about 65% of the loading dose of the deuterated arachidonic acid or an ester thereof per day is administered as a maintenance dose. In an embodiment, the maintenance dose is utilized to ensure that the therapeutic concentration of deuterated arachidonic acid is maintained in vivo such that a reduced rate of disease progression is maintained.
- In one embodiment, said periodic administration of the loading dose comprises administration of from about 0.05 grams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In some embodiments, the loading dose is from about 0.05 grams to about 1.5 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1.5 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1.25 grams per day. In some embodiments, the loading dose is from about 0.10 grams to about 1 gram per day. In some embodiments, the loading dose is from about 0.10 grams to about 0.5 grams per day. The loading dose may be any value or subrange within the recited ranges, including endpoints.
- In some embodiments, the loading dose is administered for at least 5 days per week, and preferably 7 days a week.
- In one embodiment, the periodic administration of the maintenance dose of deuterated arachidonic acid or an ester thereof per day comprises no more than 65% or no more than 55% of the loading dose. In embodiments, the maintenance dose is administered per day, or at least 5 days per week, or at least once per week, or at least once per month. In another embodiment, the maintenance dose comprises no more than 35% of the loading dose which is administered at least once a month.
- In one embodiment, the periodic administration of the maintenance dose is calibrated to be an amount of D6-AA or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
- In some embodiments, the loading dose is administered for between about one month and about 4 months. In some embodiments, the loading dose is administered for between about 1 month and about 2 months. In some embodiments, the loading dose is administered for about 1 month. The length of time may be any value or subrange within the recited ranges, including endpoints.
- In some embodiments, the loading dose is administered between meals. In some embodiments, the dosing is done with food, e.g. during meals.
- In some embodiments, whether the patient has a therapeutic level of D6-AA incorporated into the patient’s cells is determined by simply measuring the patient’s CRP levels. In some embodiments, the amount of D6-AA is determined based its concentration in red blood cells. In the event that the clinician determines that the patient is not responding as well as the clinician expected, an increase in either the loading dose or the maintenance dose can be made.
- In some embodiments, whether the patient has a therapeutic level of deuterated arachidonic acid incorporated into the patient’s neurons is determined. In some embodiments, the level of deuterated arachidonic acid is determined based on the amount of deuterated arachidonic acid in the patient’s red blood cells. In some embodiments, the therapeutic target is at least about 6% or at least about 12% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is at least about 15%. In some embodiments, the therapeutic target is at least about 20%. In some embodiments, the therapeutic target is between about 12% and about 30% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is between about 12% and about 25% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is between about 12% and about 20% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). In some embodiments, the therapeutic target is between about 15% and 25% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells. In some embodiments, the therapeutic target is between about 15% and about 20% deuterated arachidonic acid, based on the total amount of arachidonic acid in the red blood cells (e.g., in a blood sample). The amount may be any value or subrange within the recited ranges, including endpoints.
- In embodiments, D6-AA or an ester thereof (e.g., ethyl ester) may be administered using any dosing regimen. For example, D6-AA or an ester thereof may be administered daily, every two days, every 3 days, etc. In embodiments, D6-AA or an ester thereof may be administered for a first period of time (e.g., one week, 2 weeks, 3 weeks, 4 weeks or more), followed by a period of time where no D6-AA or an ester thereof is administered (e.g., 1 day, 2 days, 1 week or more). In embodiments, D6-AA or an ester thereof may be administered for a period of time until the therapeutic level is reached, and then administered less frequently. For example, D6-AA or an ester thereof may be administered daily until the therapeutic level is reached, and then administered every 2, 3, 4, 5, 6, or 7 days, or longer, to maintain the therapeutic level.
- The therapy provided herein can be combined with other treatments used to treat chronic inflammatory diseases. In one embodiment, D6-AA or an ester thereof can be used alone. Alternatively, D6-AA or ester thereof can be combined with 11,11-D2-linoleic acid or an ester thereof and/or with 8,8,11,1 1-D4-linoleic acid or an ester thereof. In vivo, a portion of the 11,11-D2-lineoleic acid is converted to 13,13-D2-arachidonic acid and a portion of the 8,8,11,11-D4-linoleic acid is converted to 10,10,13,13-D4-arachidonic acid.
- In another embodiment, a combination therapy can employ a drug that operates via an orthogonal mechanism of action relative to the methods described herein. Suitable drugs for use in combination include, but not limited to, antioxidants such as edaravone, idebenone, mitoquinone, mitoquinol, vitamin C, or vitamin E, provided that none of these antioxidants interfere with the therapeutic action of the deuterated linoleic acid or ester thereof.
- The specific dosing of D6-AA or ester thereof is accomplished by any number of accepted modes of administration. As noted above, the actual amount of the drug used in a daily or periodic dose per the methods of this invention, i.e., the active ingredient, is described in detail above. The drug can be administered at least once a day, preferably once or twice or three times a day.
- This invention is not limited to any particular composition or pharmaceutical carrier, as such may vary. In general, compounds of this invention will be administered as pharmaceutical compositions by any of a number of known routes of administration. However, orally delivery is preferred typically using tablets, pills, capsules, and the like. The particular form used for oral delivery is not critical but due to the large amount of drug to be administered, a daily or periodic unit dose is preferably divided into subunits having a number of tablets, pills, capsules, and the like.
- Pharmaceutical dosage forms of a compound as disclosed herein may be manufactured by any of the methods well-known in the art, such as, by conventional mixing, tableting, encapsulating, and the like. The compositions as disclosed herein can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
- The compositions can comprise the drug in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds. Such excipient may be any solid, liquid, or semi-solid that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- The compositions as disclosed herein may, if desired, be presented in a pack or dispenser device each containing a daily or periodic unit dosage containing the drug in the required number of subunits. Such a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, a vial, or any other type of containment. The pack or dispenser device may be accompanied by instructions for administration including, for example, instructions to take all of the subunits constituting the daily or periodic dose contained therein.
- The amount of the drug in a formulation can vary depending on the number of subunits required for the daily or periodic dose of the drug. Typically, the formulation will contain, on a weight percent (wt. %) basis, from about 10 to 99 wt. % of the drug based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 50 to 99 wt. %.
- In one embodiment, the drug is encapsulated in a capsule without the need for any excipients such as stabilizers, antioxidants, colorants, etc. This minimizes the number of capsules required per day by maximizing the volume of drug in each capsule.
- The present disclosure is further understood by reference to the following examples, which are intended to be purely exemplary of this invention. The present disclosure is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of this disclosure only. Any methods that are functionally equivalent are within the scope of this disclosure. Various modifications of this invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims. In these examples, the following terms are used herein and have the following meanings. If not defined, the abbreviation has its conventional medical meaning.
-
H-AA = Non-deuterated arachidonic acid (only with the natural abundance of deuterium) H-LA = Non-deuterated linoleic acid (only with the natural abundance of deuterium) D2-AA = 11,11-D2-Arachidonic Acid D6-AA = D-6 arachidonic acid having greater than 80% deuterium in the bis-allylic positions and less than 35% in the mono-allylic positions h = hours kg = kilograms LPS = lipopolysaccharide D2-LA = 11,11-D2-Linoleic Acid (aka “drug”) LA = Linoleic Acid LPO = Lipid peroxidation M = Molar mg = milligrams ROS = Reactive Oxygen Species µm = microns µm2 = square microns - LPS administration is known to promote inflammation through various mechanisms including secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS. This example employed LPS to ascertain the extent of inflammation arising from ROS induced oxidation of H-AA versus D-AA in the lungs of mice. Specifically, four groups of mice were used. The first group was control mice treated with H-LA control mice. The second group of mice received a 6-week course of D-LA. It is understood that in vivo conversion of a portion of both H-LA and D-LA occurs to provide for AA and 13,13-D2-AA respectively. The third group of mice received a 6-week course of H-AA. The fourth group of mice received a 6-week course of D-AA.
- All groups then received a single intranasal administration of LPS to induce acute lung inflammation. The degree of the inflammatory response was based on the interalveolar septa distance where the larger the distance of the septa, the greater the degree of inflammation. The animals were sacrificed and the interalveolar septa distance was measured. Table 1 provides an average degree of spatial distance for the interalveolar septa for the results of all groups.
-
TABLE 1 H-LA D-LA H-AA D-AA Interalveolar space 14.2 µm 10.7 µm 9.1 µm 4.1 µm - The above results evidence about a 25% reduction in the spatial distance for the interalveolar septa for the mice treated with D-LA relative to those treated with H-LA. However, the mice treated D-AA had almost a 60% reduction in the same spatial distance evidencing the benefits of D-AA in treating inflammation.
- LPS administration was conducted as per Example 1 above except that four groups of mice were used. The first two groups (1 and 2) were control mice (male and female). The next two groups (3 and 4) of mice received a 6-week course of H-AA (male and female). Finally, the last two groups (5 and 6) of mice received a 6-week course of D6-AA (second group).
Groups -
TABLE 2 Control (F) Control (M) H-AA (F) H-AA (M) D-AA (F) D-AA (M) Interalveolar space ~0.6 µm ~0.7 µm ~9.7 µm ~8.1 µm ~3.5 µm ~5.0 µm - The results of this experiment evidenced a statistically significant reduction in inflammation for both the male and female mice using D-AA as compared to D-LA.
- Next, the height and distance of the interalveolar septa was determined to provide for the surface area of the inflammation. The results of this evaluation are set forth in Table 3.
-
TABLE 3 Control (F) Control (M) H-AA (F) H-AA (M) D-AA (F) D-AA (M) Interalveolar surface area ~215.00 µm2 -215.00 µm2 ~380.00 µm2 -540.00 µm2 ~90.00 µm2 ~190.00 µm2 - The degree of alveolar lumen area changes in both groups of animals depended on gender. This indicator, regardless of the form of acid (H or D), in females was significantly lower than in males. However, for the male mice that received the D-form, the severity of changes in thickness of interalveolar septa was significantly higher than that of females, correlating well with human cases (females less affected). In general, the data obtained is in agreeement with the data above which indicated less inflammation in the lungs with treatment with the D-6 AA as compared to H-AA independent of the sex of the mice.
- The following examples, i.e., Examples 1a, 2a, and 3a, represent a more complete recitation of Examples 1, 2, and 3 respectively.
- LPS treatment promotes inflammation through various mechanisms including secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS. Following induction by the intranasal administration of LPS, an acute lung inflammation quickly follows. In mice receiving a 6-week course of dietary (H) AA followed by single intranasal administration of LPS, the thickness of the interalveolar septa was significantly increased, which is likely associated with stronger edema and inflammatory infiltration. Such a pronounced inflammatory infiltration of the interalveolar septa contributed to their destruction and more frequent formation of emphysema foci in this group. At the same time, lungs of mice that received the D-form were characterized by decrease in alveoli lumens, which may be associated with a lower (compared with the H-form) frequency of emphysematous transformation of the lungs. (See
FIGS. 3-6 .) - The degree of alveolar lumen area changes in both groups of animals depended on gender. This indicator, regardless of the form of acid (H or D), in females was significantly lower than in males. Besides of this among the mice that received the D-form, the severity of changes in thickness of interalveolar septa was significantly higher in males compared to females, correlating well with human cases (females less affected). In general, the data obtained indicate a lesser degree of inflammatory lesion of the lungs after course of D-form compared to H-form. Preliminary data (not shown) also indicates that D6-AA (7,7,10,10,13,13-D6-arachidonic acid) provides a better therapeutic effect as compared to other deuterated essential PUFAs. Table 4. below summarizes the data underlying
FIGS. 3-6 . -
TABLE 4 Morphological criterion Group, gender Significance Criterion, p Control, males Control, females H-ara + LPS, males H-ara + LPS, females D-ara + LPS. males D-ara + LPS, females 1 2 3 4 5 6 Alveolar lumen area (25%; 75%) µra2 185,35 (149,45: 308,70) 201,15 (156,00; 296,30) 431.1 (362,75; 554,1) 263,7 (173,85; 348,45) 112,1 73.1:209.95 ) 57,4 (46,15;104,4 ) p1-2=0.7327 p1-5=0.0000 p2-4=0.2068 p1-5=0.0225 p2-6=0.0000 p2-5=0.0000 p4-6=0.0000 Partition thickness Me (25%; 75%). µm2 3,15 (2,5,4,35) 2,8 (2,25; 3,75) 8,65 (5,3;10,8) 9,1 (7,11;11,65) 5,55 (3.2,6,7) 3,6 (3,25:4,2) p1-2=0.1264 p1-3=0.0000 p2-6=0.0000 p1-6=0.0011 p1-6=0.0473 p3-5=0.0018 p4-6=0.0000 - Oral data from human dosing in ongoing clinical trials show an impressive safety record for a similar D-PUFA drug which is a metabolic precursor to AA. The expected safety of a D-PUFA drug combined with the convenience of oral dosing of D-PUFA gel caps warrant further studies of D-PUFAs as an approach for anti-inflammatory, and possibly preventative, therapy against COVID-19 induced cytokine storm and thrombosis events. Other PUFA emulsions such as IntraLipid are formulated in emulsions and dosed I.V. at multiple grams per day safely. One could imagine such a formulation could enable rapid, bolus dosing of the drug upon treatment onset, followed up by lipid gel cap oral dosing of D-AA as a continuing therapy. These data present a rationale for further research on deuterated PUFA technology as an approach to COVID inflammation-associated therapy and other inflammation-associated conditions.
- In vitro cell-based assays for inflammation are well known in the art. These assays include such examples as e-selectin (also named Endothelial Leukocyte Adhesion Molecule or ELAM) and C-reactive protein (CRP). The ELAM assay can measure in vitro activity of test compounds in reducing expression of ELAM in activated endothelial cells.
- For example, activated endothelial cells are created by adding known activators such as lipopolysaccharides, TNF, or IL-1(3 to rat intestinal MVEC cells. Activated cells are incubated with an isotopically modified PUFA such as a deuterated PUFA (“D-PUFA”) (0.01, 0.1, 1.0, 10.0, or 100 µM of D-PUFA and 1:1 or different ratio combinations of D-PUFA mixtures, e.g. D2-LA, D4-ALA, et al., see e.g. species that fall within Formula (1) supra) or “H-PUFA” (H-PUFA means not deuterated or tritiated) (0.01, 0.1, 1.0, 10.0, or 100 µM of LA, ALA, et al., and corresponding ratio combinations of non-deuterated mixtures) for 24, 48, and 72 hours. Activated cells are known to produce ELAM, which can be measured using, for example, an E-selectin monoclonal antibody-based ELISA assay. D-PUFA treated cells are expected to produce lower amounts of ELAM as compared to cells treated with H-PUFA.
- Similarly, a CRP assay can be used to measure the in vitro activity of test compounds in reducing expression of CRP in Human Hep3B epithelial cells. For example, activated epithelial cells are created by adding known activators such as lipopolysaccharides, TNF, or IL-1(3 to Human Hep3B epithelial cells. Activated cells are incubated with D-PUFA (0.01, 0.1, 1.0, 10.0, or 100 µM), and different ratio combinations of different D-PUFAs) or H-PUFA (0.01, 0.1, 1.0, 10.0, or 100 µM of LA, ALA, and corresponding combinations of H-PUFAs) for 24, 48, and 72 hours. Activated cells are known to produce CRP, which can be measured with a CRP ELISA assay. D-PUFA treated cells are expected to produce lower amounts of CRP as compared to cells treated with H-PUFA.
- In vivo evaluation of anti-inflammatory activity can be determined by well characterized assays measuring Carrageenan-Induced Paw Edema and by Mouse Ear Inflammatory Response to Topical Arachidonic Acid. (See Gabor, M., Mouse Ear Inflammation Models and their Pharmacological Applications, 2000, which is incorporated herein by reference). Carrageenan-Induced Paw Edema is a model of inflammation that measures time-dependent edema formation following carrageenan administration into the intraplantar surface of a rat paw. Groups (8-9 animals/group) of 8-week old Wistar albino rats are supplemented with D-PUFA (see, e.g., species of Formula (1)) (0.01, 0.1, 1.0, 10.0, and 100 mg/kg), and different combinations of D-PUFAs (e.g., 1:1 ratio of two types of D-PUFAs) or H-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg) and different combinations of H-PUFA corresponding to the different combination of D-PUFA, as the only PUFA source for a period of 8 weeks. Following the supplementation period, the rats are lightly anaesthetized under isofluorane and receive a subplantar injection of 50 µL saline containing 1% w/v carrageenan. Paw volumes are determined using a water plethysmometer and compared to paw volume prior to carrageenan administration. Volumes are measured at 0.5, 1, 2, 3, 4, and 5 hr. Edema can be calculated as the increase in paw volume divided by the starting paw volume. Rats supplemented with D-PUFA are expected to have lower levels of edema as compared to Rats supplemented with H-PUFA.
- Additionally, the application of arachidonic acid (AA) to the ears of rats is known to produce immediate vasodilation and erythema, followed by the abrupt development of edema, which should be maximal at 40 to 60 min. The onset of edema is believed to coincide with the extravasations of protein and leukocytes. After one hour the edema should wane rapidly and the inflammatory cells should leave the tissue so that at 6 hours the ears will have returned to near normal. Groups (8-9 animals/group) of 8-week old male rats are supplemented with D-PUFA (see, e.g., species of Formula (1)) (0.01, 0.1, 1.0, 10.0, and 100 mg/kg of D-PUFA, and different combinations of D-PUFAs (e.g., 1:1 ratio of two types of D-PUFAs) or H-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg) and different combinations of H-PUFA corresponding to the different combination of D-PUFA, as the only PUFA source for a period of 8 weeks. Following the supplementation period, arachidonic acid is applied to the ears of the rats and vasodilation, erythema and edema is measured as a function of time. Rats supplemented with D-PUFA are expected to have lower levels of edema as compared to Rats supplemented with H-PUFA.
- Groups (8-9 animals/group) of DBA/1 mice 8-10 weeks of age are supplemented with D-PUFA (see, e.g., species of Formula (1)) (0.01, 0.1, 1.0, 10.0, and 100 mg/kg of D-PUFA, and different combinations of D-PUFAs (e.g., 1:1 ratio of two types of D-PUFAs) or H-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg) and different combinations of H-PUFA corresponding to the different combination of D-PUFA, as the only PUFA source for a period of 8 weeks. Mice are then injected with 100 µg bovine type II collagen in Freund’s complete adjuvant (FCA) intradermally at the base of the tail and monitored by daily examination for the onset of disease, which is recorded. D-PUFA treated mice are expected to have a delayed onset, it any onset, of arthritis symptoms as compared to H-PUFA treated mice.
- Alternatively, forty-five DBA/1 mice 8-10 weeks of age are injected with 100 µg bovine type II collagen in Freund’s complete adjuvant (FCA) intradermally at the base of the tail and monitored by daily examination for the onset of disease, which is recorded. At the first appearance of clinical evidence of arthritis, mice are divided randomly into one of three treatment groups: 1) control; 2) D-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg), and 1:1 or different combinations of different species of D-PUFA) treated; or 3) H-PUFA (0.01, 0.1, 1.0, 10.0, and 100 mg/kg), and 1:1 or different combinations of H-PUFA corresponding in type to D-PUFA combinations. The severity of arthritis in the affected paw is graded according to an established score system as follows: 0 (normal joint), 1 (mild/moderate visible edema and swelling), 2 (severe edema with distortion of paw and joint) and 3(deformed paw or joint with ankylosis). The sum of the scores for all four paws in each mouse is used as an arthritis index (maximum score/mouse = 12) to represent overall disease severity and progression in the animal. Animals re clinically assessed for disease five times per week until ten weeks after disease onset, and paw measurements are made three times per week. Arthritic paws without signs of disease at any time following treatment are considered in remission. All mice are pre-bled prior to the start of the trial, subsequently at onset of arthritis, two weeks post onset, four weeks post onset and at the completion of the trial. Sera obtained from each group is stored at -80° C. until needed. ELISA assays are performed to determine total anti-collagen antibody levels in mouse CIA. D-PUFA treated animals are expected to have reduced signs of arthritis as compared to H-PUFA treated animals and control animals.
- Excessive inflammatory damage to the lung tissue during bacterial or viral infections occurs with the involvement of dysregulated eicosanoid axis and hindered repair of complex components of cellular membranes and secreted surfactant proteolipids. Acute respiratory distress syndrome (ARDS) is an aggravating condition; ARDS is associated with aging is a contributor to mortality in as many as 40% of deaths. ARDS is often caused by bacterial or viral pneumonia. In rodents, ARDS is usually modeled as acute lung injury (ALI) by instillation of live bacteria (S. pneumoniae or P. aeruginosa) or non-specific damaging factors like ozone. Bacterial ALI can be modeled by a sterile single dose challenge with E. coli lipopolysaccharide (LPS).
-
FIG. 7A shows various PUFAs that are used. LA, linoleic acid; D2-LA, 11,11-D2-linoleic acid; AA, arachidonic acid; D2-AA, 13,13-D2-arachidonic acid (a product of in vivo enzymatic elongation/extension of D2-LA); D6-AA, 7,7,10,10,13,13-D6-arachidonic acid.FIG. 7B is a schematic showing hydrogen abstraction off a bis-allylic hydrogen, the key rate-limiting step of PUFA oxidation (both enzymatic and LPO), is inhibited by deuteration.FIG. 7C shows multiple products of non-enzymatic LPO include reactive carbonyls like HHE and HNE, which can covalently cross-link biomolecules.FIG. 7D shows numerous products of enzymatic AA oxidation are mostly pro-inflammatory and pro-thrombotic. - This approach uses the deuteration of the three oxidation prone sites within AA molecule, to substantially slow down the rate limiting step of oxidation (both enzymatic and non-enzymatic) via the isotope effect (IE). Here the effects are shown of dietary arachidonic acid (H-AA) or its hexadeuterated form (D-AA) on the lungs and gastrointestinal tract in healthy and LPS-treated mice.
- Bis-allylic D-PUFAs were produced by total synthesis and by catalytic deuteration.
- Mouse diet was from Research Diets (New Brunswick, NJ) based on fat-free AIN- 93G. Fat was added at 11,3% by weight total fat and 0,25% either normal H-AA or D- AA respectively (Table 5).
-
TABLE 5 Fat content in mice diets Fat composition of research diets H-AA (green dye) D-AA (pink dye) Saturated fat, % 7.75 7.75 High oleic sunflower, % 3.1 3.1 H-linolenic (ethyl linolenate), 0.2 0.2 AA ethyl ester, % 0.25 (H-AA) 0.25 (D-AA) - Male and Female BALB/c and C57BL/6 mice were provided with standard environmental conditions i.e., 22 ± 1° C., 55 ± 5% humidity and 12 h light/dark cycle with free food and water access. At the age of six weeks, animals were split into 8 groups (n=160 total, 20 of each gender) and were continuously fed ad libitum on the diet containing either H-AA or D-AA for 2, 4, 6 or 8 weeks at the daily rate of ca. 5 g of diet per mouse for the duration of the study. The other two groups of animals (n = 40, 20 of each gender) received neither PUFA-enriched diets nor LPS served as controls. The body weight and food intake were measured once a week. After completing the appropriate diet course, half of the mice in each group (10 females and 10 males) (i) underwent the procedure of bronchoalveolar lavage (BAL) to accomplish cytological smears, (ii) were subjected to tissue harvesting and collection of colon contents (after humane euthanasia with lethal dose of sodium thiopental, 100 mg/kg intravenously). On the ninth week of this diet course, the other half of the group was administered 1 mg/kg of intranasal (IN) LPS from Escherichia coli O111:B4 (Sigma Aldrich) 24 hours prior to BAL and subsequent euthanasia. 40 D-AA fed animals (20 males, 20 females) were switched to the H-AA diet for washout experiments.
- Briefly, lungs were lavaged three times using three aliquots of 1 ml 0.15 M NaCl under deep anesthesia (sodium thiopental). Each lavage consisted of slow infusion and gentle aspiration of saline via tracheal cannula. Three recovered lavages were combined. The samples were centrifuged for 7 minutes at 400 g and 4° C. in a microcentrifuge with a F241.5P rotor (Beckman Coulter, USA). The supernatants were collected and stored frozen at -80° C. no longer than one month before further analysis.
- Cell differential counts were performed on smear slides from resuspended cell pellets of BAL, using commercially available May-Grünwald-Giemsa staining kits. All slides were evaluated in a light microscope (Optec BK5000) at X200 magnification. These cell counts such as lymphocytes, neutrophils, plasmacytes and macrophages were obtained from 10 fields of each slide.
- Lung, stomach and colon samples were fixed with 4% formaldehyde (freshly prepared from paraformaldehyde), paraffin embedded and cut into 2-4 µm sections. For routine histology, all fixed tissue sections were stained with hematoxylin-eosin (H&E). All slides were evaluated at 10 fields each using a Genetic Pro Bino light microscope (A) and photographed with a digital camera (Delta Optical). Stomach and colon tissue sections were analyzed for signs of active and chronic inflammation, formation of lymph follicles, and hyperplasia of epithelial cells. The severity of lung injury was scored according to lung pathological changes, including interalveolar and perivascular hemorrhages, peri- vascular and peribronchial infiltration, perivascular edema, thickness of alveolar wall, alveolar space value, and emphysematous transformations. Lung tissue samples were additionally stained with commercially available Martius Scarlet Blue (MSB) stain kit (Avantik, USA) for fibrin visualization. The presence of homogeneous fibrin masses of yellow, pink or red color in the lung blood vessels were interpreted as thrombotic masses.
- Colon contents of euthanized mice were collected for microbial community analyses, immediately frozen and stored at -20° C. until analyzed. The samples were slowly thawed at +4° C., serial dilutions (10-3) were prepared, plated on specific media and incubated at 37° C. as follows. Microaerophylic flora: Enterococci - Enterococcal agar, 48 h; lactobacilli - Lactobacagar, 3 days; bifidobacteria - Bifidum-medium, 5 days, at 37° C.; Aerobes: Staphylococci - medium N10 for 48 h, coliforms - Endo medium for 48 h at 37° C., yeast-like fungi - Saburo agar, 48 h. These specific media were purchased from GNC PMIB (Obolensk, Russia). At the end of the specified incubation periods, colony forming units (CFU) were counted.
- Cell free BAL fluid supernatants as well as colon tissue samples were analyzed using commercially available Mouse IL-1β ELISA Kit (R&D systems, Lot P265854, USA) and the Biotek ELx-808 microplate reader (Biotek, USA) according to the instructions recommended by the manufacturer).
- The relative ratio of H-AA to D-AA was determined by gas chromatography (GC) coupled to chemical ionization mass spectrometry. Briefly, freshly harvested samples were homogenized and extracted by the Bligh and Dyer method, placed in tubes, solvent evaporated, blanketed with dry nitrogen, sealed, and shipped to Austin (TX) for further sample preparation and analysis. Dried samples were converted to fatty acid methyl esters (FAME) by a one-step method of hydrolysis and methylation. Solvent-medicated (SM) chemical ionization was performed with CH3CN as reagent using a Shimadzu GCMS-TQ8040 (Columbia, MD) instrument with a BPX70 capillary column (25 m × 0.22 mm × 0.25 µm; Trajan, Pflugerville, TX). D-AA was chromatographically separated from H-AA. Total ion chromatograms were used to integrate peak areas.
- Experimental data were processed using the Statistica 10.0 software package. Data are shown in graphs as medians and interquartile ranges (Me; Q25%; Q75%). For intergroup comparison, the nonparametric Kruskell-Wallace test was used, with adjustment for multiple comparisons. Differences were considered statistically significant at with p equal to or less than 0.05.
- In our first experiment, we evaluated the effects of linoleic acid (LA) supplementation on interalveolar septa thickness and AS in LPS-treated mice. In this experimental setting, mice (six weeks old, both genders) received PUFAs of interest once per day via
oral gavage 50 µL per mice. Upon completion of PUFA-treatment mice were intranasally administered with 1 mg/kg of LPS and sacrificed 24 hours later for lung histology. The results (FIG. 8 ) demonstrate a small, but statistically significant decrease of alveolar wall thickness in D2-LA mice when compared to H-LA group. This could be explained by a more pronounced hyperallergic response of lungs to H-LA compared with D2-LA. LPS treatment revealed signs of hyperplasia of bronchial epithelium and its hypersecretion, focal perivascular and peribronchial lymphoid infiltrates together with the presence of serous edema. Histologically, this effect was accompanied by inflammatory cells infiltration through alveolar walls. - Since D2-LA is partially converted to D2-AA by the action of fatty acid desaturases 1 and 2 (FADS 1 and FADS2) and by fatty acid elongase 5 (ELOVL5), we hypothesized that the aforementioned effects of D-PUFA can be attributed to deuteration of AA, and that direct D6-AA supplementation would be much more efficient than that with D2-LA.
-
FIG. 8 shows the thickness of interalveolar septa (µm) of BALB/c mice after 6 weeks of H- or D-forms of linoleic acid (H-LA and D2-LA) followed by single intranasal administration of lipopolysaccharide. * - p≤0.05, compared H-LA versus D2-LA mice. - As the first step to test this hypothesis, we studied the metabolic effect of such a dietary supplementation. We determined the actual content of D-AA and then performed a washout experiment after a long period of supplementation by switching from D-AA to H-AA diet by MS analysis of several mouse tissues in the AA-diet fed mice. Twelve weeks of dosing on D-AA results in more than 60% incorporation of the deuterated form (around 90% of all AA as D6-AA except for brain which had 70% of all AA as D6-AA) (
FIG. 9 ) -
FIGS. 9A-9C shows D-AA as a % of all AA at eight weeks dosing and washout over the subsequent 9 weeks with H-AA feeding.FIG. 9A shows the graphs for visceral organs and skin. Lung incorporated about 45% D-AA.FIG. 9B shows graphs for neural tissue: whole brains and whole eyes. Both incorporated about 50% D-AA. Washout from eyes was more rapid than brain.FIG. 9C shows lung D-AA and conversion to longer chain PUFA adrenic acid (22:4) by elongation and docosapentaenoic acid (DPA, 22:5) by desaturation. All PUFA followed similar washout kinetics. - Brain fatty acid metabolism tends to be distinct from that in the visceral tissues, including in overall turnover. Neural PUFA are uniquely unsaturated, with AA and omega-3 docosahexaenoic acid (DHA) together comprising about 40% of all brain fatty acids, while linoleic acid is below 1%. Lungs are similar to other tissues.
- H-AA and D-AA were well tolerated without apparent adverse reactions. Consumption of the diets for 2, 4, 6 or 8 weeks did not lead to significant changes in the level of IL-1β in BAL fluid or large intestine homogenates of conventionally healthy mice, regardless of gender. Macroscopically, the lungs of all groups were normal at the time of euthanasia. Cellular infiltration in the BAL was not significantly affected by either of AA-rich diets. After 8 weeks of feeding AA-rich diets, the number of lymphocytes increased compared to the control. The number of inflammatory cells in cytological smears of lavage was not significantly different between dietary consumption of H- and D-forms.
- The effects of the AA diets on interalveolar septa thickness depended on duration and were affected by deuteration. The average thickness of mice interalveolar septa after H-AA and D-AA diets given for 2 or 4 weeks did not significantly differ. On the other hand, alveolar walls of healthy males and females after 8 weeks of H-AA consumption were significantly (p≤0.05) thicker compared to those in respective D-AA-cohorts. No relevant changes of alveolar spaces were observed for AA or for D6-AA diets. Analysis of the composition of the intestinal microflora, as well as the enzyme immunoassay of the interleukin level in lavage and intestinal homogenates, did not reveal any significant differences between mice on the diets regardless of the dietary course duration (data not shown).
- We challenged mice fed AA-diets for 6 weeks using LPS treatment. Twenty-four hours after exposure to LPS, the lung tissue showed intense perivascular, peribronchial, and septal inflammatory infiltration, with a predominance of lymphocytes and macrophages. Perivascular edema, signs of thrombosis, alveolar wall thickening, irregular distribution of air spaces, and focal areas of alveolar hemorrhage were also observed. We preferred intranasal administration to the more extreme intratracheal route that induces IL-1β which in turn amplifies inflammation making it difficult to distinguish between the early and late consequences of the LPS challenge. Indeed, 24 hours after intranasal administration of LPS at a dose of 1 mg / kg, there was no significant increase in the IL-1β content in BAL fluid or colon homogenates compared to animals not treated with LPS regardless of type or duration of the diets. Intranasal LPS 24 hours post administration increased neutrophils in BAL fluid in all treated groups regardless of gender or form of AA diets. Counts of other inflammatory cells in LPS-treated animals changed similarly with these of non-treated mice and were characterized by significantly higher numbers of lymphocytes after 8 weeks of consuming either H- or D-AA compared to 2 weeks course of H- AA No statistically significant differences between the effects of H- and D-AA were noted for any of the analyzed inflammatory cell types, regardless of gender and LPS treatment.
- In mice receiving a 6-week course of dietary H-AA followed by single intranasal administration of LPS, the thickness of the interalveolar septa was significantly increased, which is likely associated with more edema and greater inflammatory severity accompanied by immune cell infiltration. At the same time, lungs of some mice that received H-AA and challenged with LPS showed areas of emphysematous transformation (
FIGS. 10A-10C ).FIGS. 10A-10C show histological evaluation of the effect of intranasal administration of lipopolysaccharide on the lungs of H-AA and D-AA treated male mice.FIG. 10A corresponds with normal mice lungs;FIG. 10B correspond with lung of mice that are LPS-treated on H-AA diet;FIG. 10C corresponds with lungs of mice that are LPS-treated on D-AA diet. The arrow in the figures point to emphysematous areas. - LPS-induced perivascular edema as measured by alveolar wall thickness in mice consuming H-AA contrasted with a significantly milder effect in the male D-AA group, and almost negligible in D-AA females (
FIG. 11 ) -
FIG. 11 shows graphs of the thickness of interalveolar septa (µm) after 6 weeks course of H- or D-AA by single intranasal administration of LPS. Norm, male and female mice without LPS treatment. * - p≤0.05, H-AA female mice versus control females; ** - p≤0.05, H-AA male mice versus control males; # - p≤0.05, H-AA female mice versus D-AA females; ## - p≤0.05, H-AA male mice versus D-AA males. - Gender differences are well known to be important in models like ALI. For example, female mice respond more severely to P. aeruginosa. It is believed that estrogen imparts protective effects on LPS-induced acute lung inflammation and hemorrhagic shock-induced lung injury. Conversely, in infectious models that employed P. aeruginosa, females displayed a more robust lung inflammatory response while displaying higher bacterial loads. This underscores the complexities underlying the sex differences in lung immune responses. In our study, the degree of alveolar lumen area changes in both groups of animals also depended on gender: this indicator was significantly lower in females than in males regardless of the form of AA (H or D). Also, in mice on D-AA the severity of changes in thickness of interalveolar septa were significantly higher in males compared to females, correlating well with human cases.
- ARDS can result from direct (e.g. pneumonia, acid aspiration) or indirect (e.g. pancreatitis, non-pulmonary sepsis) injury to the lungs. Murine models of direct ALI include those in which agents are delivered intratracheally or intranasally. We induced ALI by intranasal administration of E. coli LPS, considered to be a common inductor of lung injury and inflammation. Dietary consumption of H-AA prior to LPS exposure, depending on its duration, did not improve and even aggravated LPS-induced lung tissue damage, including alveolar wall thickening. The damaging effect of LPS observed against the background of dietary D-AA was substantially mitigated. LPS-induced ALI is a well-established model of ARDS. LPS activates NF-KB and then NLRP3 inflammasome, leading to secretion of IL-1β and IL-18, which further triggers inflammation by positive feedback. Although various treatments reportedly protect from acute LPS effects in the murine models like ouabain, and various other compounds like xanthohumol and corylin, the mechanisms of these protective effects are complex.
- In contrast, D-PUFA may have a simpler inflammation-reducing mode of action. We have previously demonstrated the inhibitory effect of bis-allylic deuteration of AA on the formation of various pro-inflammatory eicosanoids, while simultaneously inhibiting LPO. This combination of these useful features prompted us to test D-PUFAs in an animal model of inflammation.
- In vivo, some of the ingested LA is incorporated into most tissues, with notable exceptions including the retina and brain. Depending on tissue, a variable fraction of LA is converted into AA by enzymatic elongation and desaturation. Neural tissue contains AA but not LA, while in adipose tissue the predominant n-6 species is LA. AA derived from LA through the enzymatic elongation and desaturation is then incorporated into essentially every tissue. Accordingly, dosing mammals on D2-LA would lead to 13,13-D2-AA (
FIGS. 7A-7D ) tissue incorporation. Deuteration at C13 might lead to inhibition of COX1/2 as well as 15-LOX, reducing the level of some pro-inflammatory species as well as LPO. Indeed, our preliminary experiments revealed that although LPS-induced changes in alveolar morphology were found in mice consuming both H- or D2-LA for 6 weeks, the thickness of the interalveolar septum was significantly higher in mice treated with H-LA compared to D2-LA group regardless of gender. Consumption D-AA for 6 weeks led to a greater protective action against LPS-induced interalveolar wall thickening. Moreover, the difference in effects on the alveoli between H- and D-AA diets was even more prominent compared to that of LA isoforms. Based on our preliminary findings, a larger inhibitory effect would be expected from fully deuterated D6-AA compared to D2-AA. - AA is more efficiently incorporated into tissues when consumed as pre-formed AA rather than as LA, with subsequent metabolic conversion to AA. Nevertheless, within a tissue or pool (e.g., plasma phospholipids), AA levels tend to be controlled within relatively tight limits. One effect of dietary AA is the increase in metabolic turnover of tissue AA.
- LPS activates phospholipase A2 leading to the release of free AA into surrounding tissues and blood, modulating overall inflammation on the organism level including sepsis and survival. Accordingly, metabolism of fatty acids may be important for modulation of the acute LPS-induced lung disorder and other conditions. Exogenous oxidized phospholipids induce hyperinflammatory reaction in vitro. Omega-3 PUFAs downregulate inflammation by competing with AA for LOX and COX. Moreover, some oxidation products of long chain PUFAs (e.g., isoprostanes, and neuroprostanes) have interesting biological activities. In mice infected with P. aeruginosa survival was im-proved by fish oil supplementation. Surprisingly, these effects can be also seen with AA, whereby a single AA bolus resulted in an increase of superoxide dismutase (SOD), decreased the activity of myeloperoxidase (MPO), reduced malondialdehyde (MDA), lowered lactate dehydrogenase (LDH), alleviated PQ-induced histological damage, and inductions of inflammatory cytokines. This indicates multiple mechanisms of acute chronic responses, perhaps involving pro-resolving action of some of the AA oxidation products, such as asthma-relevant pro-resolving mediators (SPMs) like PGE2, and LXB4
- In bacterial infections, the situation is more complex because some microorganisms like common opportunistic pathogen P. aeruginosa produce a secreted from of lipoxygenase that oxidizes AA.
- AA is the major PUFA involved in inflammation. For example, peripheral blood lymphocytes and monocytes have been reported to have an average AA content of 16- 20% of total fatty acids. AA cleaved and released by phospholipase A2 (PLA2) acts as a substrate for COX, LOX and cytochrome P450, yielding pro-inflammatory eicosanoid mediators and regulators such as prostaglandins, leukotrienes, and thromboxanes. Patients with acute COPD have increased AA content in sputum. It is suggested that the severity of emphysematous transformations may also correlate in such patients with high AA levels and COX2 converted mediators. In our study, dietary consumption of D-AA for 6 or 8 weeks significantly decreased endotoxin-induced peribronchial infiltration and improved both alveolar spaces and thickness of interalveolar walls compared to those in mice receiving H-AA. Inflammation and emphysema observed in lungs of mice consuming H-AA was substantially reduced in mice dosed on D-AA, suggesting that i) increased formation of eicosanoids from dietary H-AA and ii) successful displacement of n-6 PUFA in lung and surfactant PLs by D-AA (more stable to both enzymatic and non- enzymatic oxidation) results in decreased production of COX- and LOX-converted mediators as well as decreased PLA2 stimulation by oxidative stress.
- Pulmonary surfactant covers the large alveolar surface in all mammalian species, stabilizing the alveoli and preventing them from collapse. It is composed of 10% protein and 90% lipids with a predominance of phospholipids (PLs). Within PL, both acyl chains can be either saturated (no double bonds), monounsaturated (one double bond), or polyunsaturated (i.e., more than one double bond, such as in ARA). The structure of surfactant PLs permits them to modulate the host-pathogen interaction as well as to react on environment-induced oxidative stress. Alterations of the pulmonary surfactant system have long been documented in ARDS or, more generally, in any lung disease with pronounced alveolar inflammation. Large surfactant aggregates from patients with ARDS (including ones associated with lung infection) or pneumonia are characterized by a significant decrease in the percentage of palmitic acid, whereas the relative amount of unsaturated species (including ARA) in PL is significantly increased. Multiple double bonds of polyunsaturated fatty acids make them sensitive to enzymatic and non-enzymatic oxidation, increasing the oxidative stress. Although an intra-alveolar microenvironment is often considered not to be in direct physical contact with the plasma pool, there is some evidence suggesting that systemic metabolic status as well as dietary perturbations can modulate the surfactant Pls. Continuous enteral feeding with a fish oil-enriched formulation fostered significant modulation of the PUFA composition of rat surfactant phospholipids within 72 hours. Thus, the n-6 PUFAs (i.e., 18:2n-6 and 20:4n-6, the precursors of eicosanoids and leukotrienes), were displaced by longer chain n-3 PUFA. The ability of enteral feeding to rapidly modulate the PUFAs composition of surfactant may facilitate timely attenuation of eicosanoid-driven inflammatory processes and decrease the risk of developing ARDS
- Excessive AA is pro-inflammatory under certain conditions of viral and bacterial infections that can be modelled by LPS. LPS treatment promotes inflammation through various mechanisms including the secretion of pro-inflammatory cytokines, eicosanoids and induction of ROS. Following the intranasal administration of LPS, an acute lung inflammation quickly follows. The COVID-19 pandemic is causing severe morbidity and mortality across the globe. Advanced age and other pre-existing conditions result in elevated mortality among COVID-19 patients. Many viruses have high affinity towards receptors found in the lungs. COVID-19, SARS, MERS and influenza (as well as some non-infectious diseases) trigger an immune response, attracting immune cells to the region to attack the virus, resulting in localized inflammation. In some cases, ‘cytokine storms’ ensue, involving excessive uncontrolled production of pro-inflammatory cytokines/chemokines including IL-6, TNF-α, IFN-γ, IL-2, and IL-7, resulting in hyperinflammation that can be fatal. The immune system of younger people is more reliant on innate mechanisms, so it usually produces lower levels of inflammation-driving cytokines. Additionally, COVID patients demonstrate an increased incidence of thrombotic complications (almost half of the patients admitted to the ICU), even with thromboprophylaxis, further contributing to the high mortality rate from COVID due to pulmonary embolism, strokes, and heart attacks. Indeed, AA as well as its oxidation products are elevated in COVID patients.
- There is a complex microflora involvement in diverse reactions connected to inflammation. Gut microbiota is known to be important for lung infection severity. However, we did not observe any significant differences here - this fact points to the importance of molecular mechanisms intrinsic to the mammalian cells and tissues.
- Traditional approaches to mitigating the adverse effects of eicosanoid-mediated excessive inflammatory response rely on small molecule inhibitors of COX and LOX enzymes. This, however, can lead to an aggravation of pulmonary symptoms like in the case of aspirin-aggravated respiratory disease where dysregulated AA metabolism plays an essential role. Thus, D-AA may represent a milder approach to treatment of inflammatory lung pathologies.
- Oral data from human dosing in ongoing clinical trials show an impressive safety record for D2-LA, a metabolic precursor to 13,13-D2-AA. The expected safety of a D-PUFA drug combined with the convenience of oral dosing of D-PUFA gel caps warrant further studies of D-PUFAs as an approach for anti-inflammatory, and possibly preventative, therapy against COVID-19 induced cytokine storm and thrombosis events. Other PUFA emulsions such as IntraLipid are formulated in emulsions and dosed I.V. at multiple grams per day safely. One could imagine such a formulation could enable rapid, bolus dosing of the drug upon treatment onset, followed by lipid gel cap oral dosing of D-AA as a continuing therapy. These data present a rationale for further research on D-PUFA technology as an approach to COVID inflammation-associated therapy.
- D-AA is less prone to either enzymatic or non-enzymatic oxidation and so is more potent in regulatory interactions that do not require chemical conversions. In high-fat diet mice, AA reduces the LPS-triggered inflammation in macrophages and septic death in mice through binding to MD2. Thus, in addition to its enhanced stability, D-AA may also be beneficial due to its improved metabolism. D-AA may be a viable therapeutic for inflammatory conditions involving enzymatic and non-enzymatic oxidation.
- While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the disclosure be limited by the specific examples provided within the specification. While the disclosure has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. Furthermore, it shall be understood that all aspects of the disclosure are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (9)
1. A method for controlling chronic inflammation in a patient which method comprises administering an effective amount of a composition comprising D6-arachidonic acid to said patient for an effective period of time to treat the inflammation in the patient.
2. The method of claim 1 , wherein the chronic inflammation is associated with chronic pain in said patient and said control of said chronic inflammation reduces the level of chronic pain associated therewith.
3. The method of claim 1 wherein said D6-arachidonic acid or an ester thereof having the formula where some or all of the hydrogen atoms at the 7, 10, and 13 positions have been replaced with deuterium.
5. The method of claim 3 , wherein said D6-arachidonic acid is a composition comprising arachidonic acid or an ester thereof that, on average, have at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, no more than about 35% of the hydrogen atoms at the mono-allylic sites have been replaced by deuterium atoms.
6. The method of claim 1 , wherein the amount of D6-arachidonic acid or ester thereof administered to said patient is sufficient to provide a concentration of D6-arachidonic acid in the red blood cells of said patient of at least about 12 % based on the total concentration of arachidonic acid in said red blood cells including the D6-arachidonic acid.
7. A pharmaceutical composition comprises a pharmaceutically acceptable excipient and from about 100 mg to about 2,000 mg of a composition of D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, has no more than about 35% of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
8. The pharmaceutical composition of claim 7 , wherein said composition comprises from about 100 mg to about 1,000 mg of a composition of D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, has no more than about 35% of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
9. The pharmaceutical composition of claim 7 , wherein said composition comprises from about 100 mg to about 750 mg of a composition of D6-arachidonic acid or an ester thereof that, on average, has at least about 80% of the hydrogen atoms at each of the bis-allylic sites replaced by deuterium atoms and, on average, has no more than about 35% of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/069,886 US20230301956A1 (en) | 2021-12-21 | 2022-12-21 | Methods and compositions for treatment of inflammatory disease |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163292388P | 2021-12-21 | 2021-12-21 | |
US202163293208P | 2021-12-23 | 2021-12-23 | |
US18/069,886 US20230301956A1 (en) | 2021-12-21 | 2022-12-21 | Methods and compositions for treatment of inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230301956A1 true US20230301956A1 (en) | 2023-09-28 |
Family
ID=86903593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/069,886 Pending US20230301956A1 (en) | 2021-12-21 | 2022-12-21 | Methods and compositions for treatment of inflammatory disease |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230301956A1 (en) |
WO (2) | WO2023122199A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190231733A1 (en) * | 2011-04-26 | 2019-08-01 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7048976B2 (en) * | 2015-11-23 | 2022-04-06 | レトロトップ、 インコーポレイテッド | Site-specific isotope labeling of 1,4-diene system |
JP7132630B2 (en) * | 2016-11-17 | 2022-09-07 | レトロトップ、 インコーポレイテッド | Isotope-modified moieties and their therapeutic uses |
CA3097744A1 (en) * | 2018-04-20 | 2019-10-24 | Retrotope, Inc. | Stabilized polyunsaturated compounds and uses thereof |
WO2020102596A1 (en) * | 2018-11-15 | 2020-05-22 | Retrotope, Inc. | Deuterated compounds, compositions, and uses |
JP2023513759A (en) * | 2020-02-12 | 2023-04-03 | レトロトップ、 インコーポレイテッド | Deuterated polyunsaturated fatty acids or esters thereof for cosmetic applications |
US20210251933A1 (en) * | 2020-02-14 | 2021-08-19 | Retrotope, Inc. | Methods for treating tauopathy |
IL295783A (en) * | 2020-02-21 | 2022-10-01 | Retrotope Inc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
US11491130B2 (en) * | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
-
2022
- 2022-12-21 US US18/069,886 patent/US20230301956A1/en active Pending
- 2022-12-21 WO PCT/US2022/053693 patent/WO2023122199A1/en unknown
- 2022-12-21 WO PCT/US2022/053687 patent/WO2023122195A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190231733A1 (en) * | 2011-04-26 | 2019-08-01 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
Also Published As
Publication number | Publication date |
---|---|
WO2023122195A2 (en) | 2023-06-29 |
WO2023122195A3 (en) | 2023-08-31 |
WO2023122199A1 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE49238E1 (en) | Alleviating oxidative stress disorders with PUFA derivatives | |
Paul et al. | Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease | |
US10342773B2 (en) | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient | |
US6180671B1 (en) | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected | |
ES2510690T3 (en) | Method to extend life expectancy and delay the onset of age-related disease | |
JP6082596B2 (en) | Replacement therapy for Alzheimer's disease and the aging brain | |
Deng et al. | Molecular mechanisms of ferroptosis and relevance to inflammation | |
US20100105773A1 (en) | Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization | |
Bannenberg | Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators | |
UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
US20120277317A1 (en) | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases | |
Sztolsztener et al. | α-lipoic acid ameliorates inflammation state and oxidative stress by reducing the content of bioactive lipid derivatives in the left ventricle of rats fed a high-fat diet | |
US20230301956A1 (en) | Methods and compositions for treatment of inflammatory disease | |
JP2013216679A (en) | Medicament for prophylaxis and/or therapy of non-alcoholic steatohepatitis | |
Yang et al. | Dietary fish oil enriched in very-long-chain polyunsaturated fatty acid reduces cardiometabolic risk factors and improves retinal function | |
Molchanova et al. | Deuterated Arachidonic Acid Ameliorates Lipopolysaccharide-Induced Lung Damage in Mice. Antioxidants 2022, 11, 681 | |
WO2004110426A1 (en) | Modulation of airway inflammation in patients with cystic fibrosis and related diseases | |
Pascoal et al. | New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease | |
RU2712229C2 (en) | Ethers of trihydroxyheptane acid as fpr2 receptor agonists | |
Nieto et al. | Mechanisms involved in the attenuation of intestinal toxicity induced by (S)-(+)-ketoprofen in re-fed rats | |
Mir | The effect of eicosapentaenoic acid on brain and platelet produced bioactive lipid mediators. The effect of eicosapentaenoic acid, docosapentaenoic acid and other polyunsaturated fatty acids on the eicosanoids and endocannabinoids produced by rat brain and human platelets using electrospray ionisation tandem mass spectrometry-based analysis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |